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Abstract 
 
Dehydroepiandrosterone, a C-19 steroid, is found endogenously with the highest circulating serum 
levels.  It is converted to important steroids such as the sex hormones oestrogen and testosterone. 
DHEA has come under the spotlight as a purported “fountain of youth” due to its well-characterised 
age-related decline.  The supplementation of DHEA in both the elderly and those with a 
pathophysiological deficiency has been shown to be of benefit, particularly with regard to well-
being and depression.  The role of DHEA in the periphery has not been elucidated beyond its role 
as a precursor hormone in sex steroid biosynthesis, though it has been established as a 
neuroactive neurosteroid, capable of exerting neuroprotective effects in the brain.  
 
Since the importance of free radicals in aging and neurodegeneration is well established, 
investigations were conducted on the ability of DHEA to inhibit free radical generation or scavenge 
existing free radicals.  DHEA was able to significantly inhibit quinolinic acid-induced lipid 
peroxidation, a measure of membrane damage, over a range of concentrations, although the 
reduction did not appear to be dose-dependent.  This was observed in both in vitro and in vivo 
studies.  Thus, the ability of a compound to reduce the degree of lipid peroxidation may indicate its 
value as a neuroprotectant.  However, DHEA did not significantly reduce cyanide induced 
generation of the superoxide free radical, suggesting that DHEA is not an effective free radical 
scavenger of the superoxide anion and that the reduction in lipid peroxidation does not occur 
through a scavenging mechanism. 
 
Apoptosis is a physiological process which is necessary for development and homeostasis.  
However, this form of programmed cell death can be initiated through various mechanisms and too 
much apoptotic cell death results in deleterious effects in the body.  DHEA was shown not to 
induce apoptosis.  Even the lowest concentration of DHEA investigated in this thesis shows a 
remarkable decrease in the degree of apoptosis caused by intrahippocampal chemical insult by the 
neurotoxin quinolinic acid.  Cresyl violet was used to visualise tissue for histological examination 
which revealed that DHEA is able to preserve the normal healthy morphology of hippocampal cells 
which have been exposed to quinolinic acid.  Cells maintained their integrity and showed little 
evidence of swelling associated with necrosis. 
ii 
Organ culture studies were performed by assessing the impact of DHEA on several pineal 
metabolites.  The study revealed that DHEA exerted an effect on the metabolism of indoleamines 
in the pineal gland.  Melatonin, the chief pineal hormone, did not appear to be affected while the 
concentrations of N-acetylserotonin, serotonin and methoxytryptamine showed significant 
alterations.  Thus, the neuroprotective mechanism of DHEA does not appear to be mediated by an 
increase in the presence of melatonin. 
 
The biological importance of metal ions in neurodegeneration is also well established and thus the 
potential interaction between DHEA and metal ions was considered as a mechanism of action.  
Spectroscopic and electrochemical analyses were performed to determine whether DHEA is able 
to interact with metal ions as a ligand.  These reveal that DHEA does not form a strong bond with 
the metals investigated, namely copper (II) and iron (III), but that a weak interaction is evident. 
 
These investigations were conducted in a rodent model, which has neither large amounts of 
endogenous DHEA, nor the enzymatic infrastructure present in humans.  Thus, the theory that 
DHEA exerts its effects through downstream metabolic products is unlikely.  However, these 
investigations reveal that there is merit in the statement that DHEA itself is a neuroprotective 
molecule, and confirm that the further investigation of DHEA is an advisable strategy in the war 
against neurodegeneration and aging. 
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Literature Review 
 
1.1 Neuroscience  
The brain has not always been recognised as a vital organ.  In fact, Egyptians of the middle Kingdom 
(c. 2040-1786 B.C.) would scrape the brain out through the nostrils of corpses prior to mummification 
and dispose of the tissue, in sharp contrast to the preservation of the abdominal organs.  Over a 
thousand years later the situation had improved somewhat when Plato (429-347 B.C.) proposed that 
the head controlled reason and perception – although he also suggested that the heart and lungs 
were responsible for the “Noble Passions” such as courage and pride.  Later still, Aristotle (384-322 
B.C.) is credited with establishing the heart as the organ where sensations occurred, as touching the 
brain does not result in sensation being experienced (Gellatly & Zarate, 1998).  And as recently as 
the 18th Century, the belief was widespread that the contours of the skull were linked to 32 character 
traits.  This idea was proposed by the Viennese doctor, Franz Gall who named the discipline 
phrenology (Greenfield, 1997). 
 
Fortunately we are currently in a more enlightened era – the nineties were “The Decade of the Brain” 
– though doubtless the neuroscientists of the future will also be citing our mistakes.  Neuroscience 
has come a long way and numerous journals and societies are now dedicated to this specialisation. 
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1.2 Neuroanatomy 
High school biology teaches us that the basic unit of the brain is the neuron, as depicted below in Fig 
1.1).  The human brain consists of a huge number of intercommunicating neurons, in the order of 
1011.   
 
 
Fig 1.1 The diagram shows a neuron, consisting of a central mass of cytoplasm with a cell 
membrane (soma) as well as numerous neuritic extensions.  The axon conducts 
information away from the cell body, while multiple dendrites conduct information to the 
cell body (Standring, 2005; Carey, 2005). 
 
Neurons are polarised and conduct information in the form of action potentials from the patterns of 
depolarisation and repolarisation of the membrane potential.  The potential when resting is 
approximately -70mV with respect to the outside of the neuron.  Communication between neurons 
may exist in multiple configurations with the axon terminal of one neuron forming a synaptic contact 
with dendrites, axons, cell bodies or non-neural tissue such as muscle cells (Standring, 2005).  In 
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addition to the neurons, glia are present in the brain, although the current opinion is that they serve in 
a supportive function.  The most abundant glial cells are astrocytes, followed by myelinating glia and 
other non-neuronal cells cells such as ependymal cells and microglia (Bear et al, 2001) 
 
The nervous system may be categorised as the central (CNS) or peripheral nervous system (PNS), 
although the former, consisting of the brain and spinal cord is of the most relevance to this thesis.  
The brain is divided into major regions, based on ontogenetic growth and phylogenetic principles.  
The rhombencephalon is proximal to the spinal cord and comprises of the medulla oblongata, the 
pons and the cerebellum or “little brain”.  The medulla is caudal to the rest of these areas and is 
continuous with the brain stem below the foramen magnum (Standring, 2005).  The pons and 
medulla are responsible for several autonomic and homeostatic functions including respiration and 
digestion.  All the sensory and motor neurons which pass to and from higher brain regions pass 
through the hindbrain, making conduction of information one of the most important functions of the 
medulla and pons (Campbell, 1990). 
 
The next major division is the prosencephalon consisting of the lower diencephalon and upper 
telencephalon.  The former contains the hypothalamus, hypothalamic, subthalamus and epithalamus, 
whereas the telencephalon consists of the two cerebral hemispheres, which are the largest portion of 
the brain (Standring, 2005).  These hemispheres are separated by the saggital fissure (Morgan & 
Butler, 1993), although the right and left cerebral hemispheres are linked by various commissures, 
the largest and most important of which is the corpus callosum, allowing for communication between 
the hemispheres.  
 
The surface of the brain is highly convoluted and these convolutions are more highly developed in 
higher mammals.  Sulci, or “fissures”, and gyri (“ridges”) give rise to these convolutions and allow for 
a greater surface area of the brain within the cranium.  When a saggital section is taken through the 
brain, the grey and white matter are clearly visible.  Grey matter forms the cerebral cortex and below 
this lies the white matter containing nerve fibres which communicate with the cerebral cortex.  The 
basal ganglia are comprised of grey matter, but are embedded in the white matter.  Four ventricles 
exist within the brain and are filled with cerebrospinal fluid which is secreted by the choroids plexus 
(Standring, 2005). 
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Fig 1.2 Diagrammatic representation of the main features of the brain mentioned above (Carey, 
2005). 
 
1.2.1 The Hippocampus 
The term hippocampus is derived from the Greek hippos meaning horse and kampos, referring to a 
sea-monster (www.oed.com).  This brain structure of the limbic system, found on both lateral 
ventricles, is named for its resemblance to the seahorse.  This similarity may be noted below in Fig 
1.3. 
Julius Caeser Arantius designated this structure the hippocampus in the late 16th century and the 
term Ammon’s horn or Cornu Ammonis has been favoured through modern history.  The term finds 
its origins in Egyptian mythology where the god Amun was represented as a head with ram-like horns 
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(Pearce, 2001).  The regions of the hippocampus that are designated CA1, CA2 and CA3 derive their 
names from this Latin term. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.3 The figure on the left shows the location of the hippocampus in the rat brain in the 
transverse plane (http://www.bio.davidson.edu/courses/genomics/method/ 
Brainparts.html), while the diagram on the right shows the location of the hippocampus in 
the temporal lobe of the human brain from a ventral view, where the hippocampus (red) 
is within the transparent brain (grey).  
 
1.2.1.1 The Structure and Function of the Hippocampus 
The hippocampus is situated medially to the lateral ventricle in the medial temporal lobe as 
demonstrated above in Fig 1.3.  The glutamatergic system is the chief pathway involved in the 
functioning of the hippocampus which is intrinsic to learning and memory (Bear et al, 2001) and the 
hippocampus, along with the parahippocampal region and areas of the prefrontal cortex is 
responsible for declarative or cognitive memory (Carey, 2005).  It is required for the formation of new 
memories, and those with damaged hippocampi are affected in this regard.  The website 
Newscientist.com published a news piece on 12 March 2003 about a prosthetic hippocampus, 
consisting of a silicon chip which would allow those with damaged hippocampi to form new memory.  
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Fig 1.4 The diagram above clearly shows the location and anatomy of the hippocampus 
(Hansen, 2003). 
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The hippocampus consists of neurons of the dentate gyrus (DG) and Ammon’s Horn which are folded 
together in thin sheets.  The hippocampus receives input from the entorhinal cortex via the perforant 
pathway, which consists of a bundle of axons.  These axons communicate with the DG through 
synaptic connections.  The DG neurons produce mossy fibres which in turn communicate with 
neurons of the CA3 region.  Two main axonal branches of this region communicate with the fornix 
and the Schaffer collateral, connected to the CA1 region (Bear et al, 2001). 
 
 
Fig 1.5 The illustration shows the microcircuits of the hippocampus as described above (Bear et 
al, 2001). 
 
1.2.2 The Pineal Gland 
The pineal gland, identified initially by Hierophilos (325-280 BC) has historically been linked with 
spirituality, by the Ancient Greeks as a link to the Realms of Thought and most famously as 
Descartes’ “seat of the soul”.  It is colloquially referred to as the “third eye” and many believe that an 
“awakening of the third eye” may lead to spiritual enlightenment and a fuller life.  Even more 
interesting than its significance to mysticism and spirituality is its somewhat more demonstrable 
significance to neuroscience. 
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1.2.2.1 The Structure and Function of the Pineal Gland 
The gland is located on the dorsal surface of the hypothalamus, between the cerebral hemispheres in 
the human (Ebadi, 1993).  While in the rat brain, its location is more dorsal.  It is easily visible on the 
surface of the brain, as shown in Fig 1.6. 
 
Fig 1.6 The pineal gland is visible anterior to the transverse sinus (Rowett, 1962). 
 
 It is a highly vascularised tissue consisting of pinealocytes which predominate, and neuroglia.  
These pinealocytes produce both melatonin and peptides e.g. arginine-vasotocin (Brzezinski, 1997).  
The pineal gland is innervated by the sympathetic nervous system and is responsive to light intensity 
through the control of the supra-chiasmatic nucleus, and produces melatonin (Ebadi et al, 1986). 
 
1.2.2.2 Metabolism of Indoleamines by the Pineal Gland 
Pineal indole metabolism is responsible for the production of the indoleamine melatonin from 
tryptophan in the pinealocytes (Reiter et al, 2000) and the synthesis of melatonin exhibits a circadian 
rhythm that is well documented (Reiter, 1987; Lam et al, 2004).  The production of melatonin declines 
with age when susceptibility to immune dysfunction, cancer, infectious disease and oxidative damage 
increases (Zhang et al, 1999). 
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Further description of the metabolism of the pineal gland, as well as a diagram detailing its three 
main metabolic pathways and enzymes involved in these syntheses is included in Chapter 6: Pineal 
Organ Culture Studies. 
 
1.3 Neurotoxins 
Neurotoxins are substances that are poisonous to nervous tissue.  Some substances are 
endogenous to organisms, yet when concentrations are raised, these become neurotoxic.  An 
example of this is quinolinic acid, discussed below.  Chemicals can be used as neurotoxins to mimic 
destruction in certain pathological conditions such as the use of MPTP in a model for Parkinson’s 
Disease (Freyaldenhoven et al, 1997), and kainic acid (Leite et al, 2002) and pentylenetetrazole 
(Hansen et al, 2004) to induce seizures or epileptogenesis. 
 
1.3.1 Quinolinic acid as a neurotoxin 
Quinolinic acid (QA or 2,3-pyridine dicarbolic acid) is an amino acid which occurs endogenously in 
the human brain.  This amino acid is structurally related to L-glutamate and L-aspartate and is a 
metabolite in the tryptophan-kynurenine pathway (Lapin, 1978), as shown below in Fig 1.7. 
 
QA is produced by activated monocytes and macrophages in vitro (Saito et al, 1993) and human 
microglia have been shown to convert the precursor L-tryptophan to QA (Heyes et al, 1996). 
QA is a potent activator of the N-methyl-D-aspartate (NMDA) group of glutamate receptors (Stone 
and Perkins, 1981; Stone, 2001a), thereby exerting its neurotoxic properties.  The authors showed it 
to be approximately 25% as active as NMDA itself.  Unlike its structural analogues L-glutamate and 
L-aspartate, a high affinity, rapid uptake system for QA is not present in the brain (Foster et al, 1984). 
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Fig 1.7  The diagram illustrates the metabolic pathway of quinolinic acid (Stone, 2001). 
 
The enzyme 3-hydroxyanthranilic acid oxygenase (3-HAO) is responsible for the synthesis of QA 
from its precursor, 3-hydroxyanthranilic acid, and the reaction velocity of this enzyme has been 
shown to be 80 times faster than that of quinolate phosphoribosyl transferase (QPRT), the enzyme 
which metabolises QA to its degradation products (Foster et al, 1986).  3-HAO has been found in 
areas of the brain such as the hippocampus which have little detectable QPRT so the introduction of 
increased levels of QA may lead to excitotoxic damage and a cognitive decline and memory loss 
resembling Alzheimer’s disease (Stone, 1993). 
 
The combination of these factors explains the potency of QA, an endogenous substance, as a 
neurotoxin since it is not adequately removed from the synaptic cleft and can thus continue to 
stimulate NMDA receptors. 
 
Although QA is found endogenously, its physiological role is still unclear.  However, researchers have 
determined that QA is found in increased concentrations in various pathological conditions, including 
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convulsions (Lapin, 1981), Huntington’s Disease (Schwarcz et al, 1986), hepatic encephalopathy 
(Moroni et al, 1986) and AIDS-related neurological disorders (Brown, 1990).  It is implicated in many 
neurodegenerative diseases (Beal et al, 1986). 
 
QA exposure results in excitotoxic damage characterised by raised cytosolic Ca2+ concentration, 
depletion of ATP and gamma-aminobutyric acid GABA, as well as oxidative cell death (Santamaría et 
al, 2003).  The ability of QA to induce seizures and direct neural death when injected 
intracerebroventricularly has been demonstrated (Lapin, 1978; Schmidt et al, 2000; Lara et al, 2001).  
Schauwecker (2002) reported that 120nmol QA administered intrahippocampally produces Stage 5 
seizures in 75% of mice, including postural imbalance followed by clonic or tonic-clonic convulsions. 
 
Rios & Santamaria demonstrated in 1991 that QA induced lipid peroxidation and that it has been 
suggested that the free radical NO may be involved in the neurotoxicity of QA (Santamaria et al, 
1997).  The authors base their suggestion on the ability of nitroarginine to inhibit and L-arginine to 
potentiate the lipid peroxidation caused by QA.  Southgate (1998) provided evidence that melatonin, 
a well-established free radical scavenger, was able to protect against QA induced damage.  
Additionally, Fe2+ ions are released during neuronal damage for intracellular stores and the activity of 
3-HAO may be reduced by the presence of Fe2+ ions (Stone, 1993). 
 
1.3.2 Cyanide as a Neurotoxin 
Cyanide has been known to be poisonous and is very rapidly lethal due to the interruption of the 
mitochondrial electron transport chain.  Death can occur within 5 minutes, making it the suicide 
method of choice of Alan Turing, often referred to as the father of computer science, as well as Adolf 
Hitler and Eva Braun.  In the early 1980’s there was widespread panic in the USA after containers of 
Tylenol® were laced with cyanide. 
Enzymes are present in the human body to cope with trace amounts of cyanide and the normal blood 
value for cyanide is below 3.8 μmol/L (Beers & Berkow, 1999).  It is a respiratory poison and cyanide 
poisoning normally results in fatality due to the vulnerability of nerve cells of the respiratory centre to 
hypoxia (Greer & Jo, 1995). 
Cyanide has been demonstrated, through various biochemical, morphological and physiological 
means to be a potent and selective neurotoxin whose toxicity is mediated through histotoxic hypoxia, 
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consequent to mitochondrial dysfunction (Bhattacharya & Lakshmana Rao, 2001). Cyanide inhibits 
Complex IV (cytochrome c oxidase) which is the terminal electron acceptor in the mitochondrial 
electron transport chain (Isom & Way, 1984).  This cyanide-induced dysfunction results in a cascade 
of effects consisting of failure of ionic homeostasis, acidosis, elevated Ca2+ levels and lipid 
peroxidation, leading to activation of proteases, lipases and xanthine oxidases (Maduh, 1989).  The 
elevation in brain calcium (Johnson et al, 1986) and increase in free cytosolic calcium leads to 
increased oxidative stress and excitotoxcity. 
Cyanide exposure results in oxidative stress and activation of endonucleases in oligonucleosomal 
cleavage of DNA (Trump & Berezesky, 1995).  Subsequent to oxidative stress, widespread DNA 
fragmentation leading to an apoptotic type of cell death has been documented in cyanide poisoning 
(Mills et al, 1996; Mills et al, 1999), with Mills and colleagues (1996) reporting an apoptotic effect of 
cyanide in terminally differentiated PC12 cells.  Cyanide also causes surface blebbing and 
cytoarchitectural defects of neuronal cells as a consequence of Ca2+-activated phospholipases and 
proteases (Nicotera et al., 1989). 
 
1.4 Excitotoxicity 
Excitotoxicity is the ability of excitatory amino acids (EAA) to excessively stimulate post-synaptic 
receptors, thereby causing neuronal degeneration (Olney, 1995).  Glutamate, the chief excitatory 
neurotransmitter in the mammalian brain, is important in various physiological and pathological 
events, and is an example of such an EAA.  Glutamatergic neurotransmission occurs through 
ionotropic (ligand-gated ion channels) and metabotropic (G protein-coupled) receptors (Ozawa et al, 
1998).  The NMDA ionotropic glutamate receptor appears to be particularly vital for normal brain 
function, whereas excessive stimulation of the glutamatergic system may be neurotoxic (Izquierdo & 
Medina, 1997; Ozawa et al, 1998).  This overstimulation occurs when the synaptic cleft concentration 
of glutamate is increased. 
EAAs may produce neurotoxicity in one of two principle manners which may be distinguished by their 
time course and ionic dependence.  
Acute excitotoxicity may be identified by the rapid influx of sodium ions into the neuron due to 
excessive depolarisation, accompanied by passive entry of water and chloride ions due to osmotic 
pressure.  Thus the neuron swells (Tilson & Mundy, 1995). 
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Delayed excitotoxicity is NMDA receptor mediated and involves the influx of calcium ions (Ca2+).  This 
raises the intracellular concentration of Ca2+ which in turn triggers several neurotoxic enzymatic and 
metabolic processes, including the activation of calpain-1, a protease which degrades the 
cytoskeleton (Seubert et al, 1988).  The calcium ion may form Ca2+-calmodulin, which is well 
established as an enzyme modulator.  It may result in mitochondrial dysfunction or activate lipases 
(Scatton, 1994). 
The phospholipases which catabolise cell membranes are activated by Ca2+, resulting in the 
destruction of Ca2+ stores within the cell and exacerbating an already injurious situation.  Arachidonic 
acid is liberated during this process, allowing for the synthesis of prostaglandins.  These biological 
molecules are important in the inflammatory response and inflammatory cells produce reactive 
oxygen and nitrogen species (ROS and RNS, respectively) as a mechanism for opsonised targets 
(Akiyama et al, 2000). 
It has been established that increasing the expression of neuronal nitric oxide synthase (NOS) in 
culture results in increased glutamate neurotoxicity.  Neuronally originated nitric oxide is therefore 
important in behavioural function and as an excitotoxic trigger (Dawson et al, 1993). 
In the discussion of free radicals earlier in this chapter, it was noted that excess nitric oxide 
generation in the neuron may result in the production of the peroxynitrite radical if the superoxide 
anion is present.  Thus excitotoxins increase free radical production, resulting in excess release of 
glutamate extracellularly.  The entry of Ca2+ during delayed excitoitoxicity activates NOS and the 
cycle continues (Blaylock, 1999).  The mediators result in activation of the caspase cascade, and 
then in apoptotic cell death (Cassarino & Bennett, 1999). 
 
1.5 Free Radicals and Oxidative Stress 
Free radicals are any moieties, such as atoms or molecules, which possess unpaired electrons in 
their outermost orbit.  Due to this, free radicals are largely unstable and highly reactive (McMurry, 
2000).  They are well established as being necessary in many biochemical processes such as signal 
transduction and gene description (Zheng & Storz, 2000), but their effects may be deleterious due to 
their oxidant nature which harms cells and may result in cell death (McCord, 2000).  
Atmospheric oxygen exists as O2 and this molecule is a very powerful oxidising agent due to its 
ability to easily accept electrons from other molecules.  Any free radical including oxygen is referred 
to as a reactive oxygen species or ROS.  
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The aging process is accompanied by an increase free radical production due to normal processes 
and the presence of ultraviolet light.  The introduction of toxins also results in increased oxidative 
insult (Reiter, 1995).  The brain has a high metabolic activity and consumes a major proportion of 
total body oxygen (Halliwell, 1992), as much as 20%, even though it masses only 2% of body weight 
(Juurlink & Paterson, 1998).  The brain also has a high lipid content which makes it readily 
susceptible to lipid peroxidation after free radical attack, as well as a high iron content required for 
Fenton initiated free radical generation (Reiter, 1998).  Not all oxygen in cells is used for the 
production of ATP and can therefore be converted to reactive oxygen species (ROS).  
 
1.5.1 Types of Free Radicals 
 
1.5.1.1 The Superoxide Radical 
When molecular oxygen is reduced through the acceptance of an electron, the superoxide anion   
(O2• -) is created.  This moiety exists in aqueous environments in equilibrium with its conjugate acid, 
the hydroperoxyl radical, and both have been shown to participate in various biotransformations, 
including the oxidation of α-tocopherol to 8α-tocopherone (Nishikimi et al, 1980).  The superoxide 
anion also mediates the reduction of cytochrome c by xanthine and xanthine oxidase (McCord & 
Freidovitch, 1968).  This reaction is used in the assay for both the superoxide anion and superoxide 
dismutase, which are enzymes which have evolved a surface charge arrangement to make specific 
use of the superoxide anion as substrate (Benovic et al, 1983).  Activated cells such as macrophages 
produce superoxide to aid in the phagocytation and subsequent destruction of bacterial cells (Colton 
& Gilbert, 1987), which explains how chronic inflammation can lead to further damage mediated by 
free radicals. 
The superoxide free radical is implicated in a broad spectrum of diseases due to its toxicity which 
results from its ability to inhibit various enzymes and metabolic pathways.  It has varied effects on 
some of the major classes of biological molecules (McCord, 2000). 
This radical alters DNA, directly or indirectly as demonstrated by increased rates of mutagenesis in 
E. coli with SOD impairment (Touti & Farr, 1990).  
The superoxide radical may be involved in the initiation and termination steps of lipid peroxidation (as 
shown in Fig. 1.7 below).  Reperfusion after ischaemia results in increased production of SOD and is 
associated with increased lipid peroxidation (Nelson et al, 1994). 
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The superoxide radical generated intracellularly is readily converted to hydrogen peroxide through 
the acceptance of a single electron and two protons. 
 
1.5.1.2 The Hydroperoxyl Radical 
As mentioned previously, this is the conjugate acid of the superoxide radical, created by its 
protonation.  The pKa  of the hyroperoxyl radical is relatively acid, so at physiological pH little is 
present (Bielski & Allen, 1977).  However, while physiological pH is accepted as approximately 7.4, in 
isolated areas of the body, the pH may drop, increasing the relative amounts of the hydroxyproxyl 
radical.  An example of such a location is in close proximity to membranes. 
The hydroperoxyl radical is less polar than its conjugate base, so is more easily able to cross 
lipophilic membranes (Halliwell & Gutteridge, 1986), as well as being more reactive than the 
superoxide radical and may attack lipids directly, converting linolenic, linoleic and arachidonic acids 
to peroxides (Bielski et al, 1983). 
 
1.5.1.3 The Hydroxyl Radical 
Reiter (1995) refers to the hydroxyl radical as “the radical’s radical” since it may react with any 
molecule it encounters at diffusion rates.  It is arguably one of the most highly oxidising entities and is 
a “molecule destroyer”.  
Hydroxyl radicals may be generated from superoxide and hydrogen peroxide via two main routes:  
the Haber-Weiss reaction or the Fenton reaction. 
In the Haber-Weiss reaction, superoxide interacts with hydrogen peroxide to produce the hydroxyl 
radical as well as a molecule of water and a hydroxyl group as demonstrated in Equation 1. 
In the Fenton reaction (Fenton, 1894), ferric ions interact with superoxide anions, producing ferrous 
ions, which in turn interact with hydrogen peroxide to produce the hydroxyl radical as demonstrated 
in Equations 2 and 3.  
 
O2• - + H202 ? OH- + H20 + OH •     Eqn 1 
 
Fe3+ + O2• - ? O2 +Fe2+     Eqn 2 
Fe2+ + H2O2 ? Fe3+ + OH • + OH-   Eqn 3 
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It is widely recognised that the hydroxyl radical is so highly reactive that it will interact with any 
molecule within a few Angstroms of its site of production, and its half life at physiological 
temperatures may be measured in nanoseconds.  These molecules may be DNA, membrane lipids 
or carbohydrates (Dawson & Dawson, 1996, Reiter et al, 1995) and no enzyme system uses the 
hydroxyl radical as a substrate (Bird & Iversen, 1974). 
 
1.5.1.4 Nitric Oxide and the Peroxynitrate Radical 
Nitric oxide (NO) is an important physiological messenger whose roles include modulating the pyloric 
sphincter (Yun et al, 1996) and vasodilation (Holsher, 1997).  It is released most commonly by 
vascular endothelial cells and phagocytes (Moncada et al, 1991) and one of the properties which 
makes it an effective messenger is its short half-life, reported to be approximately six seconds.  This 
is explained by the presence of the superoxide radical which rapidly converts it to the peroxynitrate 
radical (Beckman et al, 1993). 
The peroxynitrate radical is highly reactive and may be able to diffuse across several cell diameters, 
damaging cells through the oxidation of lipids, proteins and DNA (Beal, 1997).  The inflammatory 
hypothesis of AD suggests that peroxynitrite production is a factor worsening neuronal degeneration 
(Torreilles et al, 1999) 
 
1.5.2 Lipid Peroxidation 
This reaction is defined as the oxidative degradation of polyunsaturated fatty acids or PUFAs, found 
in cell membranes.  Lipid peroxidation is a radical reaction and, as such, proceeds through three 
clearly defined steps: initiation, propagation and termination (McMurry, 2000). 
This degradative process can occur in the presence of any species with enough activity to abstract a 
hydrogen atom from an unsaturated carbon double bond such as the methylene group present in 
large quantities in lipids.  Examples of these highly reactive initiator moieties include hydroxyl radicals 
and iron-oxygen complexes.  Cell damage has been shown to produce hydroxyl radicals.  Abstraction 
is assisted by the presence of the carbon double bond, since the adjacent carbon-hydrogen bond is 
weakened.  The abstraction results in an unpaired electron and the formation of a carbon radical in 
the initiation step.  The carbon radical is fairly unstable so the lipid undergoes molecular 
rearrangement to form a more stable conjugated diene.  This diene combines with oxygen under 
appropriate conditions to form the peroxyl radical, ROO.. 
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The peroxyl radical then abstracts hydrogen from another lipid molecule during the propagation step.  
Another carbon radical is formed and it may react to form another peroxyl radical, continuing the 
chain reaction.  The length of this propagation chain is affected by the lipid:protein ratio in the 
membrane, the fatty acid composition, as well as the oxygen concentration and the presence of chain 
terminating anti-oxidant moieties.  These molecules provide easily donatable hydrogens and are 
abstracted by the peroxyl radicals in favour of lipid molecules during the termination step (Halliwell & 
Gutteridge, 1990).  Both peroxyl radicals and lipid peroxides attack macromolecules such as 
intramembranous protein receptors or enzymes (Reiter, 1995) which can have a deleterious effect on 
cell function. 
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Fig 1.8 Diagrammatic representation of the mechanism of lipid peroxidation (Gutteridge & 
Halliwell, 1990). 
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1.6 Cell Death 
Cell death may be broadly classified into two morphologically and biochemically distinct types, 
namely necrosis and apoptosis.  Necrotic cell death is pathological whereas apoptosis is normal 
physiological process (Wylie et al, 1998).  Whether cell death proceeds via apoptosis or necrosis is 
dependent on the type and duration of oxidative insult. 
 
1.6.1 Distinguishing between Apoptosis and Necrosis 
 
 
  
Fig 1.9 The distinct morphological changes which occur during the processes of apoptosis and 
necrosis are easily visible (www.cell-death.de/aporeview). 
 
1.6.2 Necrosis 
Cell death via necrosis occurs as a result of various pathological stimuli and is a passive process – 
membrane integrity is disturbed, cellular swelling and subsequently lysis occurs.  Necrotic cell death 
occurs very rapidly, in contrast to the delayed onset of apoptotic cell death.  Necrosis affects 
neighbouring cells and results in a significant inflammatory response (Van Furth & Zwet, 1988), as 
well as a loss of regulation of ion homeostasis.  It may be evoked by non-physiological stimuli such 
as lytic viruses, ischaemia and metabolic processes.  DNA is digested randomly (Gschwind & Huber, 
1997) and no vesicles are formed, so lysis is total, liberating cell contents.  The organelles swell and 
disintegrate (Wylie et al, 1998).  A primary effect of cell necrosis is lipid peroxidation of cell 
  1: Literature Review 
  20 
membranes.  This results in damage to surrounding tissues by destroying lipid membranes and the 
formation and release of toxic products. 
 
1.6.3 Apoptosis 
Lockshin and Williams (1964) suggested that programmed cell death follows a sequence of 
controlled steps leading to locally and temporally defined self-destruction.  The term apoptosis was 
first used by Kerr et al (1972) and is derived from Greek, meaning a falling or dropping off, in 
reference to leaves falling off trees, or petals falling off flowers.  Technically, apoptosis refers only to 
the morphological changes while programmed cell death is more appropriately used to describe the 
fundamental processes. 
The terms programmed cell death and apoptosis are frequently used interchangeably, but Schwartz 
et al (1993) maintain this is inaccurate as the authors demonstrated that not all cell death displays 
the characteristics of apoptotic cell death.  Another form of cell death (PCD2) exists in addition to 
apoptosis (PCD1) and is termed autophagy (Petersen et al, 2001).  Characteristics include 
membrane wrinkling, nuclear pyknosis (condensation) and the retention of high molecular weight 
genomic DNA (Bursch et al, 2000). 
 
 
Fig 1.10 The diagram illustrates the effect of programmed cell death on various organisms and 
demonstrates the necessity of this process (www.celldeath.de/aporeview).   
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Cell death is not necessarily a negative occurrence.  It is in fact vital for development (Clarke, 1990; 
Johnson & Deckwerth, 1993; Batistatou & Greene, 1993).  For instance, the formation of the digits 
occurs through extensive cell death of the mesenchymal tissue originally present interdigitally.  It has 
also been noted that massive cell death occurs during early development of the nervous system, 
such as at the edge of the neural plate and within the optic stalk (Kuan et al, 2000).  Other instances 
where cell death is necessary for development are shown in Fig 1.10 above. 
Hamburger and Levi-Montalcini (1949) showed that removal of limb buds in chick embryos resulted 
in histiogenetic degeneration of the corresponding spinal ganglia.  Kuan et al (2000) conclude that 
cell death modifies the initial progenitor pool, thereby modifying the developing nervous system.   
Apoptosis is the most common form of eukaryotic cell death (Wylie et al, 1998) and is a homeostatic 
process, since a balance must exist between the constant formation of new cells via mitosis and the 
death of old cells.  The process requires the de novo expression of genes and activation of these 
genes (Schwartz, 1991) and is thus an active process. 
However, the inappropriate regulation of apoptosis may play an important role in several pathological 
conditions including stroke, cancer, AIDS and neurodegenerative disorders (Delhalle et al, 2003). 
 
1.6.4 Features of Apoptosis 
Apoptotic cell death results in characteristic biochemical and morphological changes as well as 
chromosomal DNA organisation (Cohen, 1993).  The cell shrinks and is unable to maintain contact 
with neighbouring cells.  The chromatin in the cells condenses.  Budding, or blebbing, occurs 
resulting in the formation of apoptotic bodies, the occurrence of which is a primary diagnostic feature 
of apoptosis (Kerr et al, 1972).  These bodies contain cytosol, the condensed chromatin, as well as 
organelles.  These are engulfed by macrophages so no cellular contents are released and no 
inflammatory response results.  These phagocytic cells secrete cytokines such as IL-10 and TGF- 
which in turn inhibit the inflammatory response.  This is represented graphically in Fig 1.9 above.  
The fragmented DNA results in a characteristic ladder pattern in agarose gels (Wyllie, 1980).  The 
morphological changes mentioned above are initiated by activating members of the protease family 
called cysteine aspartate-specific proteases or caspases (Delhalle et al, 2003).  
 
Apoptosis may occur through one of two pathways, referred to as the extrinsic and intrinsic 
pathways.  When apoptosis occurs via the extrinsic pathway or “death receptor” the process is 
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triggered by activation of the tumour necrosis factor (TNF) superfamily which then recruits several 
procaspases.  The intrinsic pathway is the mitochondrial pathway and occurs due to mitochondrial 
release of factors which also activate procaspase.  This activation of procaspases leads to either 
activation or inhibition of target proteins which ultimately leads to apoptosis (Dehalle et al, 2003). 
 
Many conditions can result in cell death via apoptosis, and pharmacological agents such as anti-
oncogenic drugs have their effect through this form of programmed cell death.  Of particular 
relevance is the contribution of apoptosis to several neurodegenerative disorders, including AD 
(Wylie et al, 1998). 
 
1.7 Neuroprotection and Neuroprotective Strategies: Defence against Free Radicals 
One of the most documented strategies for the defence against free radicals is the use of 
antioxidants.  These molecules act by attenuating the damage caused by oxidative stress, usually by 
reacting with intermediary peroxide molecules to inhibit lipid peroxidation.  However it must be borne 
in mind that lipid peroxidation is not the only consequence of oxidative insult (Halliwell, 1992). 
 
Complex endogenous antioxidant defence mechanisms which scavenge ROS (Halliwell & 
Gutteridge, 1989; Cheeseman & Slater, 1993) include relative small molecules such as tocopherols, 
ascorbic acid glutathione and melatonin, as well as antioxidant enzyme systems such as superoxide 
dismutases, glutathione peroxidases, glutathione reductase and catalases (Frei et al, 1989; Burton & 
Ingold, 1989; Behl et al, 1997; Murphy et al, 1989; Tan et al, 1993).  These are necessary in normal 
biological function since free radicals play an integral role in many metabolic pathways and 
messengering systems as mentioned previously. Steroids have been shown to have neuroprotective 
properties by acting as antioxidants and inhibiting lipid peroxidation (Behl et al, 1997), but this is 
discussed in more detail later in this chapter. 
 
Vitmain E (alpha-tocopherol) participates in the termination step of lipid peroxidation by donating a 
phenolic hydrogen to the free radical.  Vitamin C (ascorbic acid) then regenerates Vitamin E by 
reducing the alpha-tocopherol radical, producing an ascorbic acid radical.  Neither of these radicals is 
particularly reactive due to the energetic stability of their unpaired electrons.  Ascorbic acid is in turn 
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regenerated by glutathione (Fang et al, 2002).  Lipid hydroperoxides are converted to alcohols by 
glutathione peroxidase.  
These examples are but a few of the many ROS and RNS scavengers present physiologically.  A 
more extensive, but not complete, list includes uric acid (a metabolite of purines), salicylate, mannitol, 
carotenoid, ubiquinone, bilirubin (a product of haemoglobin catabolism), -lipoate, arginine, citrulline, 
glycine, taurine, histidine, creatine (a metabolite of arginine, glycine and methionine), carnosine (-
alanyl-Lhistidine, which is abundant in skeletal muscle), tetrahydrobiopterin (a metabolite of 
guanosine triphosphate and thus glutamine), phytate, and tea polyphenols (Fridovich, 1999; Lawler, 
2002; Machlin & Bendich, 1987; Wu & Meininger, 2000; Lass et al, 2002; Akashi et al, 2001; 
Redmond et al, 1996). The key determinant of the degree of oxidative stress is thus the balance 
between the biological production and subsequent scavenging of ROS. 
 
1.8 Neurodegenerative Diseases 
These may be defined as neurological damage accompanied by a loss of neurons.  Waldmeier & 
Tatton (2004) summarise the causes that may trigger neurodegenerative disease (ND) as follows:  
 
Impaired axonal transport Glutamate receptor over-
activation 
Excessive levels of ROS 
Inadequate provision of trophic 
molecules by neighbouring 
neurons or glia 
Reduced mitochondrial 
energy production 
Increased formation/inadequate 
degradation of inappropriately 
folded proteins 
Compromised metabolic 
pathways 
Virus/prion infection  Inflammatory processes 
 
 
Vogels et al (1990) suggest that decreased neuronal cell body size, atrophy of neuronal dendrites 
and reductions in axonal terminal fields as well as neuronal loss are all factors to consider when 
explaining ND. 
 
1.8.1 Aging 
The Green Paper on Demographic Change, prepared by the European Commission extrapolates that 
by 2030 the population of Europe over 80 will have nearly doubled from 18.8 million in March 2005 to 
34.7 million twenty five years from now – the so-called “baby boomer” generation.  And by 2050, the 
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number of people over 80 years will have increased by 180%.  And Europe is not alone – a similar 
increase in the aging population is found in Australia (www.abs.gov.au/ausstats) and the United 
States (www.census.gov/population).  
This trend does not appear to be reflected in sub-Saharan Africa, where the life-expectancy at birth is 
47.1yrs, with the prevalence of AIDS set at 10% (Lahola, 2005).  Much debate exists over this figure 
since AIDS is not a notifiable disease and may not be listed as the cause of death.  However 
research into neuroprotectants is hugely important, as those suffering from AIDS experience related 
neurological problems such as AIDS dementia which may benefit from research of this kind.  
Since the development of neurodegenerative disease is strongly associated with aging, new 
challenges exist for neuroscientists to develop ways of ameliorating the effects of these debilitating 
age-related conditions.  Free radicals have been shown to play a role in the aging process 
(Campbell, 1999).  A significant correlation exists between DHEA(S) levels and total antioxidant 
capacity (Petruzzi et al, 2002) and it is postulated that the decrease in TAC in elderly subjects is 
related to changes in antioxidant systems such as DHEA(S).  Kimonides et al (1998) suggest that 
since DHEA(S) protects against excitatory amino acid-induced neurotoxicity, lowered DHEA levels 
may increase the vulnerability of the aging or stressed human brain to neurotoxic glutamate release 
after cerebral ischaemia, neural insults and neurodegenerative diseases.  DHEA has also been 
identified as a possible avenue for hormone replacement therapy in post-menopausal women since it 
influences estradiol and estrone serum concentrations (Genazzani et al, 2002).  Thus, the 
importance of research into neurodegenerative diseases cannot be underestimated. 
 
The DHEA/cortisol ratio increases with age and this alteration in serum levels may be partly 
responsible for the catabolic state that occurs with aging.  This is in contrast to the situation in the 
first and second decades when DHEA are relatively high (Baulieu, 1996). 
 
 
1.8.2 Alzheimer’s Disease 
In 1907, a German psychiatrist and neuroanatomist published a case study on Auguste D, a patient 
in her late fifties who exhibited a loss of memory and language ability.  He referred to it as a clinical-
pathological entity.  The disorder is named for Alois Alzheimer and it is the most common of the 
neurodegenerative disorders of aging (Katzman & Thal, 1989).  Today this disorder afflicts millions of 
people the world over, the largest proportion of whom are over the age of 60.  
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Alzheimer’s disease (AD) is a progressive neurodegenerative condition impairing mental function, 
memory, reason, language and self-sufficiency (Horsburg & Saitoh, 1994).  AD is characterised by 
the presence of an excessive number of senile or neuritic plaques with -amyloid cores and 
neurofibrillary tangles comprised of Tau proteins, as well as a selective distribution of cell loss.  
These do not occur throughout the brain, but in several areas including the hippocampus where the 
large pyramidal cells in the CA1 and subiculum are most affected (Katzman & Thal, 1989).  
Katzman and Thal (1989) describe the clinical presentation of AD as a progressive intellectual 
deterioration that involves memory, orientation, language functions, as well as higher brain function 
including personality, judgement, calculation, visual-spatial and constructional abilities. 
AD is accompanied by a loss of neurons in the amygdala (Vereecken et al, 1994), cerebral cortex 
and hippocampus (Beers & Berkow, 1999) and cell shrinkage as well as neuron loss in the nucleus 
raphes dorsalis (Aletrino et al, 1992) and the nucleus basalis of Meynert complex (Vogels et al, 
1990).  Van Rensburg et al (1994) have also demonstrated that lipid peroxidation is key in the 
aetiology of age-related diseases such as AD. 
In areas in which -amyloid plaques and neurofibrillary tangles are found, the enzyme responsible for 
the production of acetylcholine is reduced and thus the transmission of ACh is affected.  This is 
accompanied by degeneration of cholinergic neurons (Bannister, 1992).  The soluble oligimer of the 
-amyloid peptide has been demonstrated to activate microglia – which are important in the 
neuroinflammation associated with AD (Streit et al, 2004) – as well as inducing QA production in cells 
(Guillemin et al, 2005). 
It is widely recognised that AD accounts for almost two thirds of senile dementia cases, giving it the 
title of most common cause of dementia late in life (Katzman & Thal, 1989).  The incidence of AD 
increases with age (Beers & Berkow, 1999). 
 
Cognitive decline is inevitable in AD, since AD cannot be cured with current medical knowledge.  All 
treatments are symptomatic and although drugs which enhance cholinergic transmission modify the 
loss of memory experienced in early stages, they cannot prevent the deterioration of the fundamental 
pathology.  AD has been described as a multineurotransmitter deficiency disease, and although the 
reduction of acetylcholinesterase in the most well documented, serotonin, noradrenalin, somatostatin, 
and corticotropin-releasing factor are also reduced (Markesbery, 1997). 
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The acetylcholinesterases enhance central cholinergic function by reversibly inhibiting the enzyme 
acetylcholinesterase (AChE).  This enzyme is responsible for the degradation of acetylcholine (ACh) 
in the synaptic cleft, and its inhibition results in an increased half-life of Ach and an enhanced post-
synaptic signal (Gibbon, 2003). 
A correlation exists between decreased levels of steroids and increased levels of important proteins 
implicated in the development of neuritic plaques and neurofibrillary tangles, which supports the 
theory that neurosteroids may be protective in AD (Weill-Engerer et al, 2002) and iron accumulation 
in AD is a source of redox-generated free radicals (Smith et al, 1997), suggesting that antioxidant 
properties may be of value.  Free radicals are involved in the pathogenesis of neuron death, but 
since tissue injury also results in free radical generation, it is still unclear whether these increased 
free radicals are a cause or effect of the disease (Markesbery, 1997). 
Cerebrospinal fluid levels of QA correlate well with severity of neurological deficits, suggesting QA 
plays a direct role in the progression of neurodegenerative disorders (Takikawa, 2005).  The 
tryptophan-kynurenine pathway has been demonstrated to be up-regulated in AD, thereby leading to 
increased QA synthesis (Guillemin et al, 2005).  
It is well documented that AD patients exhibit raised levels of iron (Goodman, 1953, Ehmann et al, 
1986), which participates in the Fenton reaction to liberate free radicals as shown above, which can 
act as lipid peroxidants.  
 
1.9 DHEA 
DHEA, an intermediate hormone in the synthetic pathway from cholesterol to the sex steroids 
testosterone and oestrogen, has risen from obscurity.  Now widely referred to as a “fountain of youth” 
or even an “unknown star” (Schlienger et al, 2002), this hormone has gained new respect in scientific 
circles.  Adolf Butenandt was awarded the Nobel Prize for his work on the sex steroids, part of which 
included isolating DHEA from urine by acid hydrolysis in the early 1930’s (Butenandt & Dannenbaum, 
1934).  Its sulphated form DHEAS was first identified ten years later by Munson and colleagues 
(1944).  It once again came to the fore almost two decades later when Baulieu (1960) discovered that 
it was synthesised by the adrenal cortex. 
DHEA is a multifunctional, pleiotropic hormone whose effects are mediated through nongenomic 
actions on various neurotransmitter systems.  The hormone increases neuronal excitability, 
modulates neuronal plasticity and exhibits neuroprotective properties (Wolf & Kirschbaum, 1999). 
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A ScienceDirect (www.sciencedirect.com) search for the keyword “dehydroepiandrosterone” yields 
just over 7 330 hits in the database over all years.  Of these, over thirty percent were published with 
the last decade, and almost fifteen per cent within the last two years, showing how interest in this 
hormone has grown substantially.  
DHEAS functions as a circulating hydrophilic storage form or reservoir for DHEA.  Since the latter is 
more lipophilic, it may be converted intracellularly to androgens and oestrogens as shown in Fig 1.12 
below.  The ratios of circulating DHEAS to DHEA are 500:1 and 250:1 in men and women, 
respectively (Labrie et al, 1997).  This ratio can be explained by considering the metabolic clearance 
rates (MCR) and half-lives of these two compounds.  The MCRs are 2000L/day and 13L/day for 
DHEA and DHEAS, respectively and half-lives of DHEA and DHEAS range from 30 minutes to 7 
hours and 10 hours to 24 hours (Frye et al, 2000; Rosenfeld et al, 1975).  Another important factor is 
the weak protein-binding displayed by DHEA, while its sulphate derivative is more strongly bound 
(Kroboth et al, 1999). 
Research using exogenously administered DHEA has demonstrated that DHEA and DHEAS are 
constantly undergoing interconversion (Arlt et al, 1998; Arlt et al, 1999) and Bird and co-workers 
(1984) established that the conversion ratios for the conversion of DHEAS to DHEA were 0.006 in 
males and 0.004 in females, confirming that a substantial amount of DHEA derives from DHEAS. 
Sulphation and glucuronidation are the main conjugation pathways of Phase II metabolism.  
Sulphation of lipophilic moieties increases their water solubility - enhancing the ability of the body to 
transport and excrete these molecules.  It is well established that sulphation is a major reaction in 
steroid synthesis, transport and metabolism.  
Concentrations in the brain are somewhat different with Liere et al (2000) demonstrating that the 
concentration as assayed by gas chromatography-mass spectrometry (GC-MS) in the rat brain of the 
unconjugated neurosteroid is 0.45 ± 0.02ng/g , while that of the sulphate ester is 2.47 ± 0.27ng/g.  
Corpéchot et al (1981) show that in the rat brain, the concentration of DHEAS is up to 20 times that 
of the plasma, and exceeds concentrations in organs such as the liver, kidneys and adrenals. 
The study indicated that the biosynthesis of C-19 steroids does occur at a low rate in rat adrenals 
and the authors suggested in 1981 that DHEAS was produced or accumulated in the rat brain.  
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1.9.1 The Structure of DHEA 
 
 
Fig 1.11   The structure of 5-androsten-3--ol-17-one, otherwise known as 
dehydroepiandrosterone. 
 
Dehydroepiandrosterone (DHEA) is the steroid with the highest circulating serum concentration, 
ensuring that sufficient substrate exists for biotransformation into androgens and estrogens in 
peripheral tissues (Labrie et al, 1998).  Both DHEA and pregnenolene, the immediate precursor 
hormone to DHEA, are classed as 3-hydroxy-Δ5 compounds.  DHEA itself can be referred to as a 
precursor hormone, due to its metabolism to the important sex steroids 17--estrodiol and 
testosterone (see Fig 1.12).  This fact has caused some scientists to refer to DHEA as a “mother 
hormone”, although Baulieu (1996) argues that this is inappropriate.  DHEA has a three- to ten-fold 
predominance of androgenic over oestrogenic activity, although it gives rise to a substantial quantity 
of both androgens and oestrogens (Kroboth et al, 1999). 
The role of DHEA in the periphery has not been elucidated beyond its role as a precursor hormone in 
sex steroid biosynthesis.  
 
1.9.2 Physical Properties of DHEA 
It is a fine white or almost white crystalline powder which is freely soluble in alcohol, yet practically 
insoluble in water.  It melts between 146°C and 151°C.  It should be stored in a cool dry place and 
protected from light.  Its molecular formula is C19H28O2 and its relative molecular mass is 288.4g/mol   
(European Pharmacopoeia). 
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1.9.3 Biosynthesis 
The human adrenal gland was identified by Bartholomeus Eustachius in 1563 (Bourne, 1949).  In 
mammals it consists of a centrally placed medulla and peripheral cortex.  The main body of the 
cortex consists of columns of cells making up the zona fasciculate (ZF), as well as a more 
specialised area adjacent to the medulla which forms the zona reticularis (ZR).  These 
morphologically distinct zones, along with the outer zona glomerulosa (ZG), comprise the adrenal 
gland (Hornsby, 1999).  
Dehydroepiandrosterone, with its sulphated ester, DHEAS are the major adrenal steroid hormones.  
The ZR, which develops at adrenarche, is the site of DHEA(S) biosynthesis in the adult human 
adrenal cortex (Endoh et al, 1996).  Fig 1.12 below illustrates the adrenal biosynthesis of DHEA. 
DHEA secretion is stimulated by release of adrenal corticotrophin releasing hormone (ACTH); the 
adrenal synthesis of DHEAS is also stimulated by the hormone but normally no daily fluctuations are 
visible due to the much lower MCR (Baulieu, 1996).  In healthy females DHEA(S) is synthesised 
exclusively by the adrenal cortex, while in males as much as 25% may be secreted by the testes 
(Kroboth et al, 1999). 
It has already been established that DHEA concentrations in peripheral blood exhibit a circadian 
rhythm (Rosenfeld et al, 1975), and that this rhythm is attenuated with age, while that of cortisol (also 
produced in response to stimulus by ACTH) is largely unaffected by the aging process (Parker et al, 
2000).  Additionally, Ceserini et al (2000) determined that no significant DHEA circadian rhythm 
existed in older subjects, but a single 50mg DHEA dose restored rhythmicity and increased serum 
concentrations, thereby favourably affecting the DHEA/cortisol ratio.  
There is a wide inter-individual variability in DHEA(S), even when variables such as age and 
apparent health are taken into account (Berr et al, 1996), but the concentration serves as a highly 
specific and reliable marker in individuals (Orentreich et al, 1992), supporting the idea that a genetic 
component to the variation exists (Rotter et al, 1985). 
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Fig 1.12 This diagram depicts the site of synthesis in the adrenal glands of both DHEA and its 
sulphated derivative, DHEAS.  The relevant enzymes in the conversion from cholesterol 
are also indicated (www.med.unibs.it/~marchesi/sterhorm.html). 
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1.9.4 Distribution of DHEA 
While circulating levels of DHEAS are 100 times that of DHEA, in the cerebrospinal fluid the ratio falls 
to about 3 (Guazzo et al, 1996).  It is the most prevalent steroid of the brain in rats and humans 
(Majewska, 1995).  Robel and Baulieu (1995) reported brain:plasma ratios of 4 and 8.5 for DHEA and 
DHEAS, respectively.  DHEA is weakly bound to sex hormone-binding globulin (SHBG) and to 
albumin (Dennehy & Tsourounis, 1999).  Its sulphate ester is more strongly bound, resulting in higher 
clearance values and a longer half-life for DHEAS as mentioned in Section 1.9. 
 
1.9.5 The Metabolism of DHEA 
As previously discussed, DHEA is a precursor steroid.  Its synthesis from cholesterol via 
pregnenolene is catalysed by cytochromes P450 (Doostzadeh & Morfin, 1996) and is shown in Fig 
1.13 below.  DHEA and its sulphate ester exist in equilibrium.  Unconjugated DHEA may be 
converted to both oestrogens and androgens.  The human steroidogenic enzyme P450c17 converts 
little 17α-hydroxyprogesterone to androstenedione in the periphery.  Androstenedione synthesised 
from DHEA via 3-hydroxysteroid dehydrogenase is in turn converted to testosterone and oestradiol 
by isozymes of 17-hydroxysteroid dehydrogenase and by P450 aromatase, respectively.  Thus, the 
biosynthesis of all sex steroids proceeds through DHEA (Allolio & Arlt, 2003). 
 
Fig 1.13 The diagram illustrates the biosynthesis and metabolic conversion of DHEA.  The 
enzymes catalysing each step are numbered as follows: 1: P450scc (20,22 
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desmolases); 2: P450c17 (17α-hydroxylase); 3: P450c17 (17-20 desmolase); 4: 
sulfotransferase; 5: sulfatase; 6: 3--hydroxysteroid dehydrogenase, 7: 17--
hydroxysteroid dehydrogenase, 8: aromatase, 9: 5-α-reductase.  DHT: 
dihydrotestosterone (Cormier et al, 2001). 
 
As is visible in Fig 1.13, the enzymes responsible for the equilibrium between DHEA and its sulphate 
ester are steroid sulphatase, which catalyses unconjugated steroid formation, as well as neurosteroid 
sulfuryl transferase which in turn catalyses the formation of the sulphate ester.  In primates, studies 
characterising the specific activity of the steroid sulphatase have produced conflicting results with 
regard to the influence of gender (Lakshmi et al, 1981; Kříž et al, 2005).  Kříž and coworkers showed 
that the specific activity of steroid sulphatase declined in the female brain in the order cerebellum, 
cortex, subcortex while no major changes were observed between the regions of the male brain.  
The sulphotransferase was established in nine regions of the rat brain, with the highest 
concentrations observed in the hippocampus, frontal cortex, thalamus and basal ganglia – all four of 
which are regions involved in the control of coordination and memory (Aldred and Waring, 1999).  
The authors note that the enzyme activity in the adult rat brain is a quarter of that found in the liver 
and a third of that in the kidney. 
 
It is suggested that the modulation of neurotransmission may be through direct action on the 
neuronal membrane (Aldred & Waring, 1999) and this is supported by the fact that neurosteroids can 
cause structural changes in neurons and astrocytes (Schumacher et al, 1996).  Aldred & Waring 
(1999) also observed that the brain regions with the highest sulphotransferase activity correspond 
with the regions of highest DHEA biosynthesis in previously published results by Robel et al (1991).  
Orally administered DHEA undergoes minimal bioconversion due to first pass metabolism (Callies et 
al, 2000). 
 
1.9.6 DHEA Undergoes an Age-related Decline 
DHEA has been referred to as the “fountain of youth” or an “unknown star”.  This can be attributed, 
amongst other factors, to its well documented age-related decline.  DHEA levels have been shown to 
peak in the third decade in both males and females.  Levels post-natally are initially very high, due to 
extensive production by the foetal adrenals.  Levels rapidly drop as the foetal zone regresses and 
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minimal changes in serum concentration occur until the adrenarche.  ZR cells, which up until this 
stage have not been present in significant quantities, begin to synthesise DHEA(S).    
 
The low expression of 3-hydroxysteroid dehydrogenase (3-HSD) demonstrated by Gell et al (1996), 
Parker (1997) and Endoh et al (1996) plays a role since the inhibition of 3-HSD results in increased 
production of DHEA in human and bovine models (Hornsby, 1980).  At adrenarche 3-HSD 
expression in the ZR is suppressed, accounting for the substantial increase in DHEA(S) levels and as 
children age (Gell et al, 1996).  This can be explained since 3-HSD competes with P450c17 for 
pregnenolene. 
 
Serum levels increase to peak values in the third decade, after which an asymptotic decline is then 
apparent.  Levels in the 70-79 year old population are reported to be approximately 20% of peak 
values (Orentreich et al, 1984).  These cross sectional data were confirmed by a longitudinal study in 
normal healthy males (Orentreich et al, 1992). 
 
 
 
 
Fig 1.14 The graph, modified from Orentreich et al (1984), illustrates the distinct age-related 
decline of DHEA in both male and female human subjects. 
 
Endoh et al suggest that the most straightforward hypothesis for this age-related decline in synthesis 
by the adrenal glands is a progressive decline in zona reticularis cells in the adrenal cortex, possibly 
due to a greater susceptibility to apoptosis, which in turn is due to differences in gene expression 
between ZR and ZF cells (Khoury et al, 1987, Khoury & Berline, 1988).  Hornsby (1999) concurs with 
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the hypothesis that a loss of ZR cells is responsible for the decrease in adrenal androgen 
biosynthesis.  
A large inter-individual variation in DHEA(S) levels exists and when age is factored out of the 
equation, the residual variation is shown to have a significant genetic component (Rotter et al, 1985). 
Circulating hormones have an impact on 3HSD levels in the cells of the reticularis, thus regulating 
DHEA(S) biosynthesis in this region (Endoh et al, 1996). 
Morley et al (1997) demonstrated that the amount of bioavailable testosterone undergoes a similar 
age related decline due to the reduced levels of the precursor DHEA(S).  
In elderly human subjects, a once daily dose of DHEA (50mg) restored endogenous DHEA to peak 
youth levels, and subsequently increased the levels of circulating androgens and estrogens (Arlt et 
al, 1998; Arlt et al, 1999). 
Cytochrome P450 17c catalyses the hydroxylation of pregnenolene and its sulphate ester, as well as 
the subsequent removal of the side chains of these hydroxylated products (see Fig 1.12).  The lyase 
activity which results in cleavage of the side chain declines with age, resulting in less DHEA and 
subsequently less testosterone (Morley et al, 1997). 
Morley and colleagues (1997) suggest that DHEAS binds to albumin and then forms a tertiary 
complex with testosterone, enabling the targeting of specific receptors for a faster action at the 
cellular level. 
In addition to aging, the levels of DHEA(S) are affected by physiological condition.  The 
concentrations of both DHEA and its sulphated form are reduced during the progression of the HIV 
infection (Christeff et al, 1992; Grinspoon & Bilezikian, 1992).  In a murine AIDS model, Zhang et al 
(1999) showed that DHEA affected immune dysfunction and prevented hepatic lipid peroxidation.  
This murine retrovirus has been demonstrated to be remarkably similar to HIV (Liang et al, 1996).  
Robinzon & Cutolo (1999) argue that the replacement of DHEA may be of value with glucocorticoid 
therapy as it ameliorates the deleterious effects of the latter.   
 
1.9.7 Receptor for DHEA  
To date, no specific DHEA receptor has been identified in the plasma membrane, nucleus or 
cytoplasm (Kaasik et al, 2003), although the hormone has been shown to interact nonspecifically with 
receptors in murine and human t-lymphocytes which also effectively bind dihydrotestosterone (Allolio 
&  Arlt, 2003).  DHEA has been shown to be a negative modulator of GABAA (Majewska et al, 1990), 
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possibly through the picrotoxin site (Sousa & Ticku, 1997), a positive modulator of NMDA receptors 
(Wu et al., 1991) and a sigma1 receptor agonist (Romieu et al, 2003).  
 
1.9.8 The Myriad Effects of DHEA 
 
1.9.8.1 DHEA and General Well-being 
Supplementation of DHEA in the elderly has resulted in observations of improved well-being, 
determined by factors such as improved quality of sleep, increased energy, a greater sense of 
relaxation, and an improved ability to handle stress (Morales et al, 1994), irrespective of gender.  
This is supported by Glei et al (2004) who furthermore observed that higher DHEA levels may be 
associated with better self-rated health.  An increase in libido has also been reported in the DHEAge 
Study by Baulieu et al (2000), as well improved skin status in terms of hydration, epidermal 
thickness, sebum production and pigmentation. 
 
1.9.8.2 DHEA and Depression 
Wolkowitz et al (1997) identified older patients with DSM-III-R Major Depression and Hamilton 
Depression Rating Scale ratings of 17 out of 21 or higher.  These patients, after being medication 
free for six weeks, received DHEA open label for four weeks and improved significantly in all 
psychiatric rating scales, specifically in the areas of cognitive disturbance and verbal memory. The 
authors acknowledge the limitations of their study (small sample size) but suggest that DHEA has 
antidepressant and cognition-enhancing effects in middle-aged and elderly patients with major 
depression.  Ritsner et al (2003) demonstrated the cortisol/DHEA ratio is raised in patients with 
schizophrenia, and that when variables such as age, illness and age of onset were controlled this 
elevated ratio correlated with depression, trait anger and hostility. 
 
1.9.8.3 DHEA and Diabetes 
It has been demonstrated that when DHEA is administered to streptozotocin-treated rats, the pattern 
of both nonenzymatic (e.g. reduced glutathione) and enzymatic (superoxide dismutase, glutathione 
peroxidase and catalase) antioxidants returns to near control values (Aragno et al, 1999), implying 
that DHEA administration may counteract the perioxidative processes involved in diabetic 
complications. 
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1.9.8.4 DHEA and Obesity 
DHEA has been shown to have effects against obesity (Bellino et al, 1995; Kalimi & Regelson, 1990).  
In addition to this, DHEA has been demonstrated to exert a synergistic anorectic effect when 
administered with d-fenfluramine, a pharmacologic agent which affects serotonin synthesis and re-
uptake in the hypothalamus (Gillen et al, 1999).  Rats receiving DHEA supplementation consume 
fewer total calories, hypothesised by Pham et al (2000) to be due to the acute release of 
norepinephrine, epinephrine and dopamine in select regions of the hypothalamus.  
 
1.9.8.5 DHEA and the Cardiovascular System 
Bonnet et al (2003) have demonstrated that 30mg/kg every two days results in the prevention of an 
increase in pulmonary artery hypertension, cardiac right ventricle hypertrophy and pulmonary artery 
remodeling in a chronic hypoxic-pulmonary hypertension model in rats.  Additionally, hypertensive 
rats experienced a rapid decrease in pulmonary artery hypertension after oral or intravascular 
injection.  Furthermore, DHEA does not affect systemic pressure, cardiac outflow, left ventricle 
contraction, and heart rate, suggesting a specific activity of DHEA on pulmonary circulation.  
 
1.9.8.6 DHEA and Bone Mineral Density 
Several independent studies on the effects of DHEA on bone mineral density (BMD) and bone 
turnover markers have shown a positive correlation with DHEA supplementation in elderly subjects 
(Labrie et al, 1997, Baulieu et al, 2000, Villareal et al,).  DHEA supplementation results in a fairly 
rapid increase in BMD as well as serum osteocalcin concentration, an established marker of bone 
formation.  This is accompanied by a decrease in urinary hydroxyproline excretion, indicating a 
decrease in bone resorption (Labrie et al, 1997).  Cormier et al (2001) suggest that the ability of 
DHEA to improve bone mineral density appears to be related to both these factors, but suggest that 
this may, however, be due to conversion to the sex steroids, rather than attributable to DHEA itself. 
A number of elderly patients in a DHEA replacement trial independently reported an improvement in 
pre-existing joint pains and mobility (Morales et al, 1994). 
 
1.9.8.7 DHEA and the Immune System  
DHEA has been identified as a therapeutic agent for the treatment of the chronic autoimmune 
rheumatic disease of unknown aetiology Systemic Lupus Erythematosus (SLE).  Norman (2001) 
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outlines the clinical trials indicating that oral administration of DHEA in the form of GL-701, a 
pharmaceutical preparation, resulted in a reduction in the rate of SLE exacerbations, as well as 
allowing a reduction in the concurrent steroid dosage in patients.  
DHEA significantly elevated hepatic phospholipids in retrovirus infected mice and was shown to 
significantly increase vitamin E levels when administered in combination with melatonin.  Both these 
levels were shown to significantly decline with retrovirus infection (Zhang et al, 1999).  The authors 
concluded that DHEA and melatonin treatment significantly prevented immune dysfunction, 
excessive lipid peroxidation and loss of tissue vitamin E induced by retrovirus infection (Zhang et al, 
1999). 
Low levels of DHEA have been established in patients with breast (Zumoff et a, 1981) and prostrate 
(Stahl et al, 1992) cancer.  Additionally, the anti-oncogenic properties of DHEA have been 
demonstrated in animal models (Schwartz et al, 1986). 
 
1.9.8.8 DHEA and Melatonin 
DHEA(S) and melatonin have several effects in common, namely immune system enhancement, life 
span prolongation and cancer prevention (Milewich et al, 1995; Reiter, 1998; Agrasal et al, 2001). 
Haus et al (1996) showed that murine adrenals incubated with melatonin caused a dose-dependant 
increase in production and/or secretion of DHEA.  The authors suggest that the age-related decline 
of DHEA and melatonin may be partially due to a decrease in mutual stimulation, thus studying this 
interaction may be of value in light of the potential neuroprotective characteristics of these hormones. 
It is suggested that the pineal gland may modulate adrenal cortical function and therefore play a role 
in the age-related decline of DHEA secretion (Haus et al, 1996). 
 
1.9.8.9 DHEA and Aging 
It has already been established that DHEA serum levels undergo an age-related decline (see Fig 
1.14, Orentreich et al, 1984).  Thus the restoration of these serum levels to levels found in younger 
subjects, as well as the resultant effect on neuroendocrine metabolic functions is an area of interest.  
Morales et al (1994) found that 50mg DHEA daily, administered orally was sufficient to achieve the 
desired result, and that levels were raised from placebo values within two weeks.  The topic of DHEA 
supplementation in the elderly was explored in the DHEAge Study, which was conducted to establish 
how and when DHEA should be administered.  Baulieu et al (2000) suggests that in addition to 
examining supplementation in the aging population due to a physiological decline in concentration, 
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studies could be conducted with a “pathological end-point” in mind.  The relative risk of death for men 
was reported to be highest with lowest levels of DHEAS and low levels of DHEAS proved to be a 
reliable predictor of death in male smokers (Mazat et al, 2001). 
 
The administration of steroids may be a pharmacological route to the amelioration of age-related 
changes in the CNS for the following reasons: 
1 Steroids are important in the functioning of both the central and peripheral nervous 
systems. 
2 Several steroids have been suggested as neuroprotectants. 
3 Several neuroactive steroids undergo an age-related decline. 
4 Due to their lipophilic nature, unconjugated steroids readily cross the blood-brain 
barrier and are accumulated within the brain (Schumacher et al, 2003). 
 
1.9.8.10 DHEA and Alzeimer’s Disease 
Research regarding the link between DHEA(S) levels and AD is unclear.  Low DHEAS levels are risk 
factors for AD (Hillen et al, 2000) when human subjects were matched for age, gender, morbidity and 
immobility, while Berr and colleagues did not observe lowered DHEAS levels in subjects with 
prevalent dementia or AD.  
However, Brown et al (2003) have demonstrated that DHEA levels in the brain and cerebrospinal 
fluid are raised in patients with AD relative to age-matched controls, contrasting with situation of 
decreased serum levels, suggesting the CSF and serum levels of DHEA can be used diagnostically 
in the examination of AD neuropathology.  The addition of ferrous sulphate to sera of controls caused 
an increase is DHEA, which was not observed in sera from AD patients (Brown et al, 2003). 
Brown et al (2003) showed that although DHEA levels were increased in AD patients, 
immunoreactivity to P450c17 was not evident, indicating that an alternative pathway for the synthesis 
of DHEA exists in the brain, and that this pathway is activated by increased oxidative stress.  The 
authors also suggest an alternative precursor which may be use to identify AD closer to the onset of 
the disease, or establish the progression of AD.  The question remains whether DHEA has a role in 
the pathology of the disease, or whether it is merely an epiphenomenon. 
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1.9.9 Neurosteroids and Neuroactive Steroids 
The term “neurosteroid” was coined by Etienne-Emile Baulieu in 1981 for a group of hormones with 
certain properties.  Robel and Baulieu (1998) explain that neurosteroid refers to steroids which 
accumulate in the brain independently of endocrine glands and undergo de novo synthesis within the 
nervous system.  These steroidal compounds must also exert physiological/pharmacological actions 
on neuronal cells in central and peripheral nervous system (Gasior et al, 1999).  Although the 
synthesis of DHEA in the zona reticularis has already been mentioned, the hormone is entitled to be 
termed a neurosteroid due to its ability to undergo de novo synthesis in the brain, independently of 
the peripheral endocrine pathway detailed above (Aldred & Waring, 1999).   
Additionally, DHEA is a neuroactive steroid, as DHEA synthesised in the adrenal gland has been 
demonstrated to have an influence in the CNS.  This neurosteroid exerts neurotrophic effects with 
extensions in the processes of neurofilament-positive neurons and glial fibrillary acid protein-positive 
astrocytes (Roberts et al, 1987).  Compagnone and Mellon (1998) provided evidence that DHEA 
selectively increases the length of neurites with the axonal marker Tau-1, while DHEAS increased 
the length of those with the dendritic marker MAP-2.  
Oligodendrocytes and astrocytes are able to produce DHEA via an alternative pathway that is 
independent of P450c17 and that the oxidative environment of the brain may have an effect on glial, 
but not neuronal, formation of DHEA (Brown et al, 2000).  The authors suggest this may be 
influenced by elevated levels of endogenous ROS. 
Steroidogenic enzymes including cytochrome P450 cholesterol side-chain cleavage (P450scc), 
aromatase, 5α-reductase, 3α-hydroxysteroid dehydrogenase and 17-hydroxysteroid dehydrogenase 
have been identified in the brain through molecular and biochemical investigations (Stoffel-Wagner, 
2001). 
DHEA was first recognised as an adrenal steroid hormone (Baulieu, 1960) but researchers have 
realised in the half-century since the afore-mentioned discovery that both adrenal and gonadal 
hormones are not merely responsible for reproduction, but these hormones may be neurally 
important (Schumacher and Robert, 2002; Schumacher et al, 2000) since free steroids are 
sufficiently lipophilic to cross the blood-brain barrier. 
The panicogenic agent pentagastrin causes the release of neuroactive steroids such as DHEA and 
allopregnenolene (Tait et al, 2002), although the reason for this is undetermined. 
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1.9.10 DHEA and Neuroprotection 
DHEA decreases the neurodegeneration caused by 1-methyl-4-phenylpyridium (MPP+) induced 
neurotoxicity in the rat nigrostriatal dopaminergic system (Tomas-Camardiel et al, 2002).  Estradiol 
and testosterone were also tested, though only the former was found to be protective.  The authors 
suggested that DHEA exerts its neuroprotective effect by partially preventing the MPP+ induced 
inhibition of NADH oxidase activity, while estradiol was thought to reduce the uptake of the toxin into 
the dopaminergic neurons.  DHEA is effective in reducing the catecholeamine depletion associated 
with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration (D’Astous et al, 2002) and 
the investigators conclude that DHEA is neuroprotective of dopaminergic (DA) neurons. 
DHEA is able to completely reverse the age-related significant decrease in corticotrophin-releasing 
hormone in the hypothalamic paraventricular nucleus, which may be correlated with general 
impairment of cerebral activity.  This result may be due to the estrogenic influence of DHEA on CRH 
gene expression but it is unclear whether DHEA or its metabolites are responsible or whether the 
regulation may be influenced by a more indirect action (Givalois et al, 1997).  However, Suzuki et al 
(2004) demonstrated that while DHEA stimulated human neural stem cell growth and affected the 
number of cells labelled with BrdUrd, neither pregnenolene, nor six other steroids found in the 
metabolic pathway of DHEA had any effect.  
 
Neurons in culture experience improved survival and differentiation when exposed to DHEA(S) in the 
nanomolar range (Bologa et al, 1987).  Human neural stem cells exposed to DHEA undergo more 
neurogenesis after differentiation (Suzuki et al, 2004) and the hormone positively regulates the 
number of neurons produced in culture from human neural stem cells. This is the first steroid tested 
to have such a marked effect. 
 
DHEA’s action is dose-dependent as Mastrocola and colleagues (2003) demonstrated that while 
DHEA was acting in an antioxidant capacity at lower doses, at high tissue concentrations, it acted in 
a pro-oxidant manner.  At doses 50mg and above daily for seven days, the neurosteroid doubled the 
level of hydrogen peroxide.  Doses below 50mg daily had no effect.  The antioxidant effect of DHEA 
at low doses was confirmed (Mastrocola et al, 2003). 
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DHEA increased neuronal survival after anoxia and Marx and colleagues (2000) established that this 
effect was not due to metabolite formation.  DHEA inhibited the toxic effects of glutamate on 
hippocampal neurons in a steroid specific and dose-dependent manner (Cardounel et al, 1999) and 
has been demonstrated to ameliorate the effects of EAA-induced neurotoxicity in both in vitro and in 
vivo models using NMDA (Kimonides et al, 1998).  DHEA has memory enhancing effects in mice 
(Flood et al, 1992, Flood & Roberts, 1988). 
 
DHEAS exerted a substantial neuroprotective effect in reversible spinal cord ischaemia model, but 
this neuroprotection was time dependent, suggesting that DHEAS may be modifying a rapid process 
initiated shortly after the start of ischaemia, or modulating a neurotransmitter function (Lapchak et al, 
2000). 
 
1.9.11 Mechanism of Action of DHEA 
A specific mechanism of action has not been identified for DHEA but the following provide a brief 
summary of the proposed mechanisms and hypotheses. 
Garthewaite & Garthewaite (1986) hypothesise that DHEA(S) exerts it neuroprotective effect by 
altering Ca2+ homeostasis after exposure to NMDA – either by reducing Ca2+ entry into cells, or by 
modifying free Ca2+ intracellularly.  May et al (1990) suggest that its neuroprotection is attributable 
rather to its nature as a glucocorticoid antagonist.  Cardounel et al (1999) provided evidence for the 
down-regulation of glucocorticoid receptors when DHEA was shown to protect hippocampal cells of 
the HT-22 line against the excitatory amino acid glutamate. 
 It has been shown that DHEA is protective of cultured neurons even when added an hour after 
NMDA insult, giving investigators reason to suggest that DHEA interfered with an unidentified 
process downstream of the initial action of NMDA (Kimonides et al, 1998).  
Researchers have suggested that the neuroprotective effects of DHEA are attributable to its role as a 
precursor hormone.  Berr et al (1996) suggest that the partial transformation to sex steroids, increase 
of bioavailable insulin like growth factor I and effects on neurotransmitter receptors may be important 
in the mechanism of action of DHEA (Berr et al, 1996; Hiroi et al, 2005).  The inhibition of the 
neuroprotective effects of DHEA against kainic acid in rats by administering an aromatase inhibitor 
caused investigators to suggest that these neuroprotective effects may be mediated, at least in part, 
by aromatase-facilitated conversion to estradiol (Veiga et al, 2003).  Jellinck et al (2001) observed 
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that the conversion rate of DHEA to androgens and estrogens was low and postulated that two major 
metabolites, 7α- and 7-hydroxydehydroepiandrosterone (7α-OHDHEA, 7-OHDHEA) may be the 
focus for further research.  These authors maintain that the hydroxylation of DHEA is not a step 
towards inactivation and elimination since DHEAS is readily produced, but rather the hydroxylated 
metabolites may have some other role (Jellinck et al, 2001) which may be related to the 
neuroprotective ability (Morfin & Starka, 2001).   
 
An antioxidant mechanism for DHEA has also been proposed (Aragno et al, 1999) as outlined in 
Section 1.9.8.3 above. 
 
Since Lapchak et al (2000) have shown that bicuculline, a GABA antagonist, attenuates the 
neuroprotective effects of DHEAS, it is suggested that its mechanism of neuroprotection is through 
the enhancement of GABAergic neurotransmission. 
Weill-Engerer et al (2003) have demonstrated that a trend towards a negative correlation between 
the density of cortical amyloid deposits and the synthesis of the DHEA metabolites 7α -OH-DHEA (in 
the frontal cortex) and ADIOL (in the hippocampus) may constitute a neuroprotective role.  They 
believe it is plausible that this metabolism regulates cerebral DHEA availability.  DHEA, as well as 
pregnenolene, have been demonstrated to be protective against amyloid-peptide induced 
neurotoxicity and amnesia (Cardounel et al, 1999; Maurice et al, 1998).  Since membrane fluidity is a 
necessary component for the function of signal transduction, DHEA may work to increase membrane 
fluidity which should facilitate lymphocyte function (Zhang et al, 1999). 
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Lipid Peroxidation Investigation 
 
2.1  Introduction 
In the thirties, J. F. Danielli and H. Davson proposed that biological cell membranes were in fact 
phospholipid bilayers, consisting of two adjacent layers of phospholipids oriented with their 
hydrophobic ends interacting.  In 1972, S. J. Singer and G. L. Nicolson expanded on this theory with 
their Fluid Mosaic Model, suggesting that proteins are a vital part of these membranes, either as 
peripheral or integral proteins (Keeton, Gould, 1993).  As shown in Fig 2.1, these dynamic 
phospholipid bilayers consist largely of lipids.  When these polyunsaturated lipids experience 
oxidative stress, this affects the way in which the oxidised molecules interact with other molecules in 
the phospholipid bilayers, thereby affecting the integrity of the cell.  The oxidative destruction of 
polyunsaturated fatty acids (PUFAs) is referred to as lipid peroxidation.  This lipid peroxidation can be 
especially destructive since chain reactions may be initiated (Reiter et al, 1996).  Membranes are 
particularly vulnerable due to their high phospholipid count (Fraser, 1985). 
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Fig 2.1 The figure illustrates the phospholipid bilayer and proteins mentioned above  
(http://www.nature.com/horizon/livingfrontier/background/images/membrane_f2.jpg). 
 
Biological oxidation is of particular significance in the brain, suggest Halliwell & Gutteridge (1990) due 
to features such as the brain’s relative glutathione deficiency as well as the fact that it is responsible 
for using a large proportion of the body’s total oxygen requirement.  Other factors such as the 
presence of large amounts of the above-mentioned polyunsaturated lipids, as well as high 
concentration of iron in some areas of the brain must also be taken into account. 
 
In 1948, Bernhein et al concluded that the coloured complex produced when thiobarbituric acid is 
incubated with certain lipids is a result of the products of oxidation of unsaturated fatty acids. 
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Thus, a simple assay of the degree of lipid peroxidation involves the measure of thiobarbituric 
reactive species (TBARS).  This test indicates the generation of hydroxyl radicals (Gutteridge & 
Halliwell, 1990).  The most abundant molecule produced as a result of oxidative stress is 
malondialdehyde (Reiter et al, 1995) and is a reliable indicator of cell damage.  This molecule reacts 
with two molecules of TBA, resulting in the production of a pale pink chromogen, the concentration of 
which can be easily established by UV Spectroscopy.   
Aldehydes are produced during the breakdown of lipid hydroperoxides in biological systems 
(Esterbauer, 1982), the most abundant of which is malondialdehyde (Schaunenstein, 1997). 
 
 
 
Fig 2.2  The reaction of MDA with TBA to yield a pink TBA-MDA complex (Mead et al, 1986). 
 
Studies to quantify MDA were performed according to the method of Das et al (1990) and Sagar et al 
(1992) which was modified by Ottino and Duncan (1997).  The assay involves incubating rat brain 
homogenate with trichloracetic acid to precipitate protein, as well as BHT to prevent additional lipid 
oxidation which may affect results.  Centrifugation causes the precipitated protein to form a pellet so 
that the supernatant may be assayed with TBA and the absorbance of MDA-TBA chromogen at 
532nm is used to determine the concentration from the standard curve generated using 1,1,3,3-
tetramethoxypropane. 
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2.2 An Investigation of the Effect of QA on Rat Brain Homogenate 
 
2.2.1 Materials & Methods 
 
2.2.1.1 Chemicals & Reagents 
DHEA was obtained from Sigma Chemicals Co, St Louis, USA.  1,1,3,3-Tetramethoxypropane (MDA) 
was obtained from Fluka AG, Switzerland.  Butylated hydroxytoluene (BHT), 2-thiobarbituric acid 
(TBA) and QA were purchased from Sigma Chemical Co, St. Louis, USA.  Trichloroacetic acid and 
butan-1-ol were purchased from Saarchem (PTY) Ltd., Krugersdorp, South Africa.  All other 
chemicals and reagents were obtained locally and were of the highest quality available. 
 
2.2.1.2 Animals 
Male Wistar rats weighing 280 to 300g were randomly divided into groups (n=5) and maintained as 
described in Appendix A: Animal Care. 
 
The rats were killed by cervical dislocation and decapitated.  The skull was lifted, after making an 
incision through the bone on either side of the parietal suture from the foramen magnum to near the 
orbits on both sides of the skull.  Care was taken to ensure the brains were not damaged during 
excision.  Brains were either used immediately or frozen using liquid nitrogen and stored at -70°C for 
later use. 
 
Whole brain homogenate was prepared in PBS (10% w/v) at pH 7.4 and ambient temperature in 
order to prevent lysosomal damage of the tissue.  A Teflon®-coated glass homogenizer was used. 
 
2.2.1.3  Preparation of the Standard Curve 
A series of standards (0-50 nmol/ml) was prepared using 1,1,3,3-tetramethoxypropane (MDA) and a 
standard curve generated by plotting the absorbance at 532nm against the molar equivalent weight 
of MDA in the complex assayed (see Appendix B: Malondialdehyde Calibration Curve).  The 
absorbance was read using a Shimadzu UV-160A UV-visible recording spectrophotometer.  Each 
point on the graph is the mean of triplicate readings. 
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2.2.1.4 The Thiobarbituric Acid Reactive Species Assay 
Clean, dry test tubes were used to prepare solutions in triplicate containing 0.8ml whole brain 
homogenate as mentioned above, 0.1ml of 50% ethanol and 0.1ml of QA, prepared in MilliQ water 
(2.5mM, 5mM or 10mM) to produce final concentrations of 0.25, 0.5 and 1mM, as well as a control 
containing no QA. 
 
Table 2.1  Scheme for assay of quinolinic acid induced lipid peroxidation.  
Control 0.8ml homogenate 0.1ml 50% EtOH 0.1ml Water 
0.25 mM 0.8ml homogenate 0.1ml 50% EtOH 0.1ml 2.5 mM QA 
0.5 mM 0.8ml homogenate 0.1ml 50% EtOH 0.1ml 5mM QA 
1 mM 0.8ml homogenate 0.1ml 50% EtOH 0.1ml 10mM QA 
 
 
After incubating for an hour, 0.5ml BHT (0.5mg/ml in methanol) and 1ml TCA (0.15g/ml in MilliQ 
water) were added.  The solutions were then covered and incubated for 15 minutes at 95°C.  After 
removal from the waterbath, solutions were then centrifuged at 2000x g for 20 minutes.  These two 
steps ensure that the malondiadehyde is released from the proteins to which it is bound, and prevent 
the adsorption of the molecule onto insoluble proteins.  
Subsequently, 2ml of protein free supernatant was transferred to a clean set of test tubes and 0.5ml 
TBA (0.33g/ml in MilliQ water) was added, followed by extraction of the MDA-TBA complex with 2ml 
butan-1-ol.  The solutions were centrifuged again at 2000 x g for 5 minutes before reading samples at 
532nm using a Shimadzu UV-160A UV-visible recording spectrophotometer.  Butan-1-ol was used as 
a blank. 
 
2.2.1.5 Statistical Analysis 
Data were analysed using ANOVA, followed by the Student-Newman-Keuls Multiple Range Test.  
The level of significance was accepted at p<0.05 (Zar, 1974). 
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2.2.2 Results 
Results are expressed as nanomoles MDA produced per milligram of wet tissue. 
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Fig 2.3  The graph shows the concentration dependent increase in induction of lipid peroxidation 
by quinolinic acid in rat brain homogenate.  The bars represent the mean + SEM; n=5.  
The differences are statistically significant (Student-Newman-Keuls Multiple Range Test, 
p<0.05). 
 
2.2.3 Discussion 
These results are consistent with those obtained by other investigators, showing that QA causes a 
dose-dependent increase in MDA production, and therefore, lipid peroxidation.  This is supported by 
the work of Rios and Sanatamaria (1991). 
 
QA is an established glutamate receptor agonist which remains in the synaptic cleft and is not readily 
metabolised or removed, allowing it to exert its effects for a prolonged period.  These include the 
opening of calcium channels, allowing for excess Ca2+ entry which in turn leads to Ca2+-mediated 
free radical generation and ultimately cell death (Stone and Perkins, 1981). 
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Stipêk et al (1996) showed that the presence of an iron chelator prevents the induction of lipid 
peroxidation, implying that the mechanism of induction – which is not well understood – may involve 
these ions.  QA forms a complex with ferrous ions and it is suggested that via this complex, QA may 
act as a pro-oxidant. 
 
Free radical formation and oxidative stress are two mechanisms whereby QA exerts its neurotoxic 
effects (Pérez-Severiano et al, 2004) 
 
2.3 An Investigation of the In Vitro Effect of DHEA on QA-induced Lipid Peroxidation  
 
2.3.1 Materials & Methods 
 
2.3.1.1 Chemicals & Reagents 
DHEA was obtained from Sigma Chemicals Co, St Louis, USA.  Butylated hydroxytoluene (BHT), 2-
thiobarbituric acid (TBA) and QA were purchased from Sigma Chemical Co, St. Louis, USA.  
Trichloroacetic acid and butanol were purchased from Saarchem (PTY) Ltd., Krugersdorp, South 
Africa.  All other chemicals and reagents were obtained locally and were of the highest quality 
available. 
 
2.3.1.2 Animals 
Male Wistar rats weighing 280 to 300g were randomly divided into groups (n=5) and maintained as 
described in Appendix A: Animal Care.  The rats were killed, the brains were removed and whole 
brain homogenate was prepared as detailed in Section 2.2.1.2 above. 
 
2.3.1.3 The Thiobarbituric Acid Reactive Species Assay 
The experiment was performed according to the method of Ottino and Duncan (1997) as detailed in 
Section 2.2.1.4 above with the following modifications:  each solution had a final concentration of 
1mM QA.  In addition, 0.1ml DHEA (prepared in 50% ethanol) was added to give a final 
concentration of 0.25, 0.5 or 1mM, as well as a control containing no DHEA.  The solutions were 
incubated at 37°C in an oscillating water bath for 1 hour and the assay continued as in Section 
2.2.1.4. 
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Table 2.2 Scheme for determining the impact of increasing concentration of DHEA on the degree 
of lipid peroxidation induced by 1mM QA. 
Control 0.8ml homogenate 0.1ml 50% EtOH 0.1ml Water 
0.25 mM 0.8ml homogenate 0.1ml 2.5mM DHEA 0.1ml 10mM QA 
0.5 mM 0.8ml homogenate 0.1ml 5mM DHEA 0.1ml 10mM QA 
1 mM 0.8ml homogenate 0.1ml 10mM DHEA 0.1ml 10mM QA 
 
 
2.3.1.4 Statistical Analysis 
The results were analysed using a one-way analysis of variance (ANOVA), followed by the Student-
Newman-Keuls Multiple Range Test.  The level of significance was accepted at p<0.05 (Zar, 1974). 
 
2.3.2 Results 
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Fig 2.4  The graph represents the effect of increasing concentrations of DHEA (0-1mM) on the 
peroxidant effect of 1mM QA as illustrated in Fig 2.3 above.  The bars represent the 
mean + SEM; n=5.  The differences between the three concentrations of DHEA were 
found to be statistically insignificant (Student-Newman-Keuls).  
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Fig 2.5  The figure shows the peroxidant effect of 1mM QA on whole rat brain homogenate, as 
well as the amelioration of this phenomenon by various concentrations of DHEA (0.25-
1mM).  The bars represent the mean + SEM; n=5.  No significant difference exists 
between the three concentrations of DHEA.  * indicates a significant decrease when 
compared to 1mM QA (p<0.001, Student-Newman-Keuls Multiple Range Test). 
 
The reduction of TBARS at all concentrations of DHEA is statistically significant when compared to 
the maximum concentration of 1mM QA, while the difference in lipid peroxidation at concentrations of 
0.25mM, 0.5mM and 1mM is non-significant.  The amount of lipid peroxidation measured in brain 
homogenate incubated with 0.5mM QA is not significantly different from homogenate incubated with 
a combination of double the concentration of QA and 0.5mM DHEA.   
 
2.3.3 Discussion 
From the above graphs it is evident that DHEA has a favourable effect on the degree of lipid 
peroxidation induced by quinolinic acid.  However, some lipid peroxidation occurs even when 
concentrations of QA and DHEA are the same, implying that the mechanism of action is not a 1:1 
interaction between the two chemicals where DHEA prevents QA from inducing damage.  Even when 
the concentration of DHEA is a quarter of that of QA, there is a significant reduction in the production 
of TBARS (p<0.001). 
**
*
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The protective effect does not appear to be dose-dependent at the concentrations used. 
 
Van Rensburg and co-workers (2000) compared the free radical scavenging abilities of DHEAS to 
that of the efficient free radical scavenger, melatonin, and found that DHEAS reduces lipid 
peroxidation at both high and low concentrations. 
 
2.4 An Investigation of the In Vivo Effect of DHEA on QA-induced Lipid Peroxidation in 
the Rat Hippocampus 
 
DHEA has been shown to have a favourable effect on lipid peroxidation in vitro.  However, an  
in vivo-in vitro correlation cannot be assumed.  The following experiment investigates whether 
subcutaneously administered DHEA can protect the brain against damage caused by chemical insult 
to the hippocampus. 
 
2.4.1 Materials & Methods 
 
2.4.1.1 Chemicals & Reagents 
DHEA was obtained from Sigma Chemicals Co, St Louis, USA.  Butylated hydroxytoluene (BHT), 2-
thiobarbituric acid (TBA) and QA were purchased from Sigma Chemical Co, St. Louis, USA.  
Trichloroacetic acid and butanol were purchased from Saarchem (PTY) Ltd., Krugersdorp, South 
Africa.  All other chemicals and reagents were obtained locally and were of the highest quality 
available. 
 
2.4.1.2 Animals 
Male Wistar rats weighing 280 to 300g were randomly divided into groups (n=5) and maintained as 
described in Appendix A: Animal Care. 
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2.4.1.3 Treatment Protocol 
The rats in each group received a daily subcutaneous injection as laid out below in Table 2.3.  
Surgery was performed on Day 8 as indicated and daily injections were continued until Day 14.  Rats 
were sacrificed by cervical dislocation.  The rats were then decapitated and the skull lifted after 
making an incision through the bone on both sides of the skull, from the foramen magnum to near the 
orbits, taking care to ensure the brains were not damaged. 
 
Table 2.3 Dosing regimen for lipid peroxidation studies 
Group Name Daily Subcutaneous Injection Bilateral Intrahippocampal Injection on Day 8
Control Vehicle PBS 
Toxin Vehicle 120nmol Quinolinic acid 
5mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
10mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
20mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
 
2.4.1.4 Surgery 
Surgery was performed on day 8.  Rats were anaethetised by placing them individually in a 
dessicator lined with cotton wool soaked in diethylether.  The rat was then placed in a rat brain 
stereotaxic frame (Stoelting, IL, USA) and level of anaethesia was maintained by placing cotton wool 
soaked in diethylether near the nose of the rat.  The proximity of the cotton wool could be adjusted 
during surgery to ensure that the rat remained at the appropriate level of unconsciousness.  This was 
determined by monitoring respiration and colour of the extremities. 
 
After a saggital incision, the cranium was exposed and the bregma identified.  Using the co-ordinates 
indicated below (König & Klippel, 1963), the hippocampus was located and 120nmol quinolinic acid 
was injected bilaterally using a Hamilton syringe with a cannula diametre of 0.3mm.    
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Relative to the bregma: 
 0.26cm laterally 
 0.40cm caudally 
0.35cm ventrally 
 
 
Fig 2.6 The diagram illustrates the position of the bregma, as well as the coronal and sagittal 
sutures (Daniels, 2002). 
 
The solutions were administered at a rate of 1μL per minute.  The cannula was left in situ for 2 
minutes following injection to ensure diffusion away from the tip into the hippocampus and reduce 
possibility of spread into the injection tract.  
The rat was removed from the stereotaxic frame and the incision was closed by suturing.  The rat 
was subsequently allowed to regain consciousness while being monitored for behavioural changes 
due to QA-induced neurotoxicity such as seizures. 
 
2.4.1.5 Sham-lesioned Rats 
The rats in the control group were treated as detailed above in Section 2.4.1.4.  However, instead of 
administering QA, an equal volume of PBS was injected intrahippocampally.  
 
2.4.1.6 Isolation of the hippocampus 
The hippocampi were carefully isolated and all adhering tissue removed.  This was performed by 
following a modified method of Glowinski & Iverson (1966).  After removal of the brain, the 
rhombencephalon was detached by a transverse section.  A further transverse section at the level of 
the optic chiasma divided the cerebrum.  The hypothalamus and striatum were subsequently 
dissected from the brain to access the hippocampus.  The mid brain was gently separated from the 
remaining portion of the brain and the hippocampus was easily isolated.      
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2.4.1.7 The Thiobarbituric Acid Reactive Species Assay 
Pooled hippocampal homogenate (10% w/v) was prepared in PBS for use in this assay.  The 
hippocampi had already been exposed to DHEA over the past 14 days, resulting in the incubation at 
37 ° C being unnecessary.  Thus 0.5ml BHT (0.5mg/ml in methanol) and 1ml TCA (0.15g/ml in MilliQ 
water) were added directly to the freshly prepared homogenate and the assay was continued as 
described previously in Section 2.2.1.4. 
 
2.4.1.8  Statistical analysis 
The results were analysed using a one-way analysis of variance (ANOVA), followed by the Student-
Newman-Keuls Multiple Range Test.  The level of significance was accepted at p<0.05 (Zar, 1974). 
 
2.4.2 Results 
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Fig 2.7    The graph demonstrates the effect of various concentrations of DHEA (5mg/kg, 10mg/kg 
and 20mg/kg) on intrahippocampal QA-induced lipid peroxidation where Control refers to 
sham-lesioned rats and Toxin refers to the group receiving a daily injection of vehicle 
alone.  Each bar represents the mean + SEM; n=5.  * represents a significant decrease 
relative to Toxin group (p<0.001, Student-Newman-Keuls Multiple Range Test) 
 
 
 
*
*
*
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2.4.3 Discussion 
The results show a statistically significant decrease in the amount of MDA produced, indicating that 
there is reduced lipid peroxidation caused by quinolinic acid insult in rats treated daily with DHEA.  
These results are supported by the in vitro work outlined in Section 2.3 above where the presence of 
DHEA caused reduced lipid peroxidation induced by 1mM QA.  QA is known to induce lipid 
peroxidation (Ríos & Santamaría, 1991).  As with the in vitro study, the reduction in lipid peroxidation 
is not dose-dependent. 
 
In all cases, groups treated with DHEA exhibit reduced levels of TBARS when compared with the 
control, indicating that DHEA doesn’t merely interact with the QA and prevent it from harming the 
tissue, but is protective of the tissues in the hippocampus by some mechanism.  This was not 
observed in the in vitro assay. 
 
Tissue disrupted by homogenisation tends to undergo lipid peroxidation more easily than healthy, 
intact tissue.  It is suggested that inactivation or dilution of antioxidants, as well as the release of 
metal ions such as iron from intracellular storage sites may explain this phenomenon (Halliwell & 
Gutteridge, 1989).  This in turn explains the formation of the MDA-TBA complex when no QA is 
present as in the controls. 
 
The results show that DHEA has the ability to oppose membrane damage via lipid peroxidation, 
suggesting that its role as a potential neuroprotectant has a basis.  The potential neuroprotection 
suggested by the DHEA dose-dependent reduction in TBARS is supported by behavioural 
monitoring.  This corresponds with the observed results in Section 2.4.  DHEA and its derivatives 
have also been shown to have a modulatory effect on membrane fluidity (Morissette et al, 1999). 
Southgate et al (1998) showed that melatonin, a well known free radical scavenger, significantly 
reduces the amount of lipid peroxidation induced by QA insult.  Thus the ability of a compound to 
reduce the degree of lipid peroxidation may indicate its value as a neuroprotectant.  
 
The peroxidative effect of QA has already been discussed in terms of its interaction with iron and the 
possible interaction between DHEA and iron is further discussed in Chapter 7: Metal Interaction 
Studies. 
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Superoxide Anion Generation Investigation 
 
3.1 Introduction  
The biological importance and generation of the superoxide radical is discussed in Chapter 1: 
Literature Review.  This may be produced due to electron leakage from the mitochondrial electron 
transport chain (McCord, 1985) or though the activation of certain enzymes leading to this reactive 
radical (Patel et al, 1986).  In this light, a simple and reliable indicator for the detection of the 
superoxide anion is desirable and the nitroblue tetrazolium assay is widely regarded as such (Ottino 
& Duncan, 1997).  In the assay, the NBT ion is converted in the presence of superoxide anions to the 
insoluble diformazan, the concentration of which can be determined at 560nm. 
 
Cyanide is used to induce the generation of superoxide anions since QA, the toxin previously used in 
Chapter 2: Lipid Peroxidation Investigation, has been demonstrated not to significantly alter the 
production of this free radical at these concentrations.  This finding holds true for other glutamate 
agonists previously investigated (Southgate, 1998).  An investigation of cyanide-induced histotoxic 
hypoxia by Johnson et al (1986) showed that KCN induces a rise in brain calcium levels.  This can 
result in the elevation of calcium in the cytosol and is related to free radical generation.  Cyanide has 
been demonstrated to inhibit anti-oxidant enzymes, which may add to its neurotoxicity (Ardelt et al, 
1989).  
 
The chapter investigates the effect of incubating whole rat brain homogenate with increasing 
concentrations of cyanide, and the resultant effect on superoxide anion production.  The effect of 
DHEA on superoxide generation is also examined. 
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3.2 An Investigation of the Effect of Cyanide on Rat Brain Homogenate 
 
3.2.1 Materials & Methods 
 
3.2.1.1 Chemicals & Reagents 
Nitro-blue tetrazolium (NBT), Nitro-blue diformazan (NBD), potassium cyanide (KCN) and bovine 
serum albumin (BSA) were purchased from the Sigma Chemical Company (USA).  Glacial acetic 
acid was purchased from Holpro Chemical Company (South Africa).  Folin’s reagent was purchased 
from Saarchem (PTY) LTD, Krugersdorp, South Africa.  All other chemicals and reagents were 
obtained locally and were of the highest quality available. 
A 0.1% NBT solution was made by dissolving the NBT in ethanol before making up to the required 
volume with Milli-Q water.  The final ethanol concentration in the incubation flasks was less than 
1.5%. 
 
3.2.1.2 Animals 
Male Wistar rats weighing 280 to 300g were randomly divided into groups (n=5) and maintained as 
described in Appendix A: Animal Care.  The rats were killed by cervical dislocation and decapitated.  
The skull was lifted, after making an incision through the bone on either side of the parietal suture 
from the foramen magnum to near the orbits on both sides of the skull.  Care was taken to ensure the 
brains were not damaged during excision.  Brains were either used immediately or frozen using liquid 
nitrogen and stored at -70°C for later use. 
 
Whole brain homogenate was prepared in PBS (10% w/v) at pH 7.4 and ambient temperature in 
order to prevent lysosomal damage of the tissue.  A Teflon®-coated glass homogenizer was used. 
 
3.2.1.3 Preparation of the Standard Curve 
A series of standards (0-400μmol/L) was prepared using NBD and a standard curve generated by 
plotting the absorbance at 560nm against the molar equivalent weight of NBD in the complex 
assayed (see Appendix C: Diformazan Calibration Curve).  The absorbance at 560nm was read 
using a Shimadzu UV-160A UV-visible recording spectrophotometer.  Each point on the graph is the 
mean of triplicate readings. 
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3.2.1.4 The Nitro Blue Tetrazolium Assay 
The method is performed according to the methods of Sagar et al (1992) and Das et al (1996), as 
modified by Ottino and Duncan (1997).  Clean, dry test tubes were used to prepare solutions in 
triplicate containing whole brain homogenate as mentioned above and various concentrations of KCN 
(0-1mM).  The solutions were incubated with 0.4ml 0.1% NBT for 1 hour in an oscillating water bath 
set to 37°C.  After incubation, the samples were centrifuged at 2000g and the remaining pellet was 
resuspended in 2ml glacial acetic acid.  The absorbance of the glacial acetic acid fraction was 
measured at 560nm and the concentration of diformazan in μmoles was determined using the 
standard curve generated in 3.2.1.3. 
 
Protein content of homogenate was determined using a modified method of Lowry et al (1951).  
Clean, dry test tubes were used to prepare a solution containing 6ml of alkaline copper reagent 
(shown in Table 3.1 below) and 1ml homogenate and allowed to stand at room temperature for ten 
minutes.  Subsequently, 0.3ml Folin’s reagent was added and tubes were vortexed and allowed to 
stand at room temperature in the dark for thirty minutes.  The absorbance was read at 500nm using a 
Shimadzu UV-160A UV-visible recording spectrophotometer and results were compared to the 
standard curve generated using 0-300 μg/ml and 1ml BSA in lieu of homogenate (see Appendix D: 
Protein Assay Calibration Curve). 
 
Table 3.1 The components of the alkaline copper reagent 
Reagent (concentration) Volume 
Copper sulphate (1%) 1ml 
Sodium Tartrate (2%) 1ml 
Sodium Carbonate (2%) 2ml 
 
 
3.2.1.5 Statistical Analysis 
Data were analysed using ANOVA, followed by the Student-Newman-Keuls Multiple Range Test.  
The level of significance was accepted at p<0.05 (Zar, 1974). 
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3.2.2 Results 
Results are expressed as μmol diformazan produced per mg protein. 
0
5
10
15
20
0 0.25 0.5 1
Concentration (mM)
NB
T 
pe
r m
g 
pr
ot
ei
n
 
Fig 3.1 The graph shows the effect of varying concentrations of KCN (0.25-1Mm) on superoxide 
anion generation in whole rat brain homogenate.  The bars represent the mean + SEM; 
n=5.  * indicates a significant difference between the three concentrations used 
(p>0.001, Student-Newman-Keuls Multiple Range Test) 
 
3.2.3 Discussion 
The results show a significant increase in superoxide anion generation in a concentration dependent 
manner in the presence of cyanide when compared to the control.  Thus, the toxin does exert toxic 
effects through increased free radical generation in this investigation and as reported previously 
(Lambat et al, 2000).  The increase of 1mM KCN is approximately 80% relative to the control and 
was selected for the subsequent investigation since it caused the greatest superoxide anion 
generation. 
 
 
 
 
*
 * 
*
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3.3 An Investigation of the In Vitro Effect of DHEA on Cyanide-induced Superoxide 
Anion Generation 
 
3.3.1 Materials & Methods 
 
3.3.1.1 Chemicals & Reagents 
Nitro-blue tetrazolium (NBT), Nitro-blue diformazan (NBD), potassium cyanide (KCN), bovine serum 
albumin (BSA) and DHEA were purchased from the Sigma Chemical Company (USA).  Glacial acetic 
acid was purchased from Holpro Chemical Company (South Africa).  Folin’s reagent was purchased 
from Saarchem (PTY) LTD, Krugersdorp, South Africa.  All other chemicals and reagents were 
obtained locally and were of the highest quality available. 
A 0.1% NBT solution was made by dissolving NBT in ethanol before making up to the required 
volume with Milli-Q water.  The final ethanol concentration in the incubation tubes was below 1.5%. 
 
3.3.1.2 Animals 
Male Wistar rats weighing 280 to 300g were randomly divided into groups (n=5) and maintained as 
described in Appendix A: Animal Care.  The rats were killed and brains were removed and whole 
brain homogenate was prepared as detailed in Section 3.2.1.2 above.   
 
3.3.1.3 The Nitro-blue Tetrazolium Assay 
Clean, dry test tubes were used to prepare solutions in triplicate containing whole brain homogenate 
as mentioned above, 1mM KCN and various concentration of DHEA (0-1mM)  The solutions were 
incubated with 0.4ml 0.1% NBT for 1 hour in an oscillating water bath set to 37°C.  The assay was 
then continued as outlined in Section 3.2.1.4 above.  
 
3.3.1.4 Statistical Analysis 
Data were analysed using ANOVA, followed by the Student-Newman-Keuls Multiple Range Test.  
The level of significance was accepted at p<0.05 (Zar, 1974). 
 
3.3.2 Results 
Results are expressed as μmol diformazan produced per mg protein.  
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Fig 3.2 The graph shows the effect of varying concentrations of DHEA (0.25-1Mm) on KCN-
induced superoxide anion generation in whole rat brain homogenate.  The bars 
represent the mean + SEM; n=5.  No significant difference exists between the three 
concentrations of DHEA (Student-Newman-Keuls Multiple Range Test). 
 
There is no significant difference in KCN-iduced superoxide generation in the presence or absence of 
DHEA. 
 
3.3.3 Discussion 
DHEA was unable to reduce the concentration dependent induction of superoxide radicals by KCN at 
the concentrations used.  DHEA does not interact with KCN at these concentrations, nor does it 
scavenge the superoxide radical.  It therefore cannot be deduced that DHEA is a potent inhibitor of 
superoxide anion generation by cyanide in the brain, and must mediate its neuroprotective effects 
through another mechanism.  Further studies on the electron transport chain may be of value to 
elucidate other effects of DHEA, as well as an investigation using higher concentrations of DHEA as 
other researchers have shown that DHEA may act as a pro- or an anti-oxidant, depending on its 
concentration (Mastrocola et al, 2003).  Additionally, KCN has been shown to elevate calcium levels 
as mentioned above, yet DHEA has been demonstrated to play a role in calcium homeostasis 
(Watter & Dorsa, 1998) and a further investigation of this may be beneficial. 
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Apoptosis 
 
4.1 Introduction 
Programmed cell death is a term used almost interchangeably with apoptosis.  More correctly, 
apoptosis is a form of programmed cell death, and not cell death itself (Schwartz et al, 1993).  The 
mechanism of this particular type of cell death is explained in Chapter 1: Literature Review.  
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling is more commonly referred 
to as TUNEL and is the most frequently used method for the identification of apoptosis.  Apoptosis 
may be identified by the apoptotic cell morphotype described by Kerr and colleagues (1972), though 
Negoescu et al (1997) maintains that the TUNEL system is more rapid and not subject to the 
variation in morphology due to fixation processes.  
Fundamentally, Proteinase K is applied to slices of tissue to facilitate access to the nuclear targets.  
The TUNEL labeling mixture is subsequently added and interacts with breaks in DNA by labeling the 
3’-OH termini. 
 
 
Fig 4.1 The diagram illustrates the labeling principle used in TUNEL staining.  The free 3’-OH 
termini interact with terminal transferase (TdT), causing labelled nucleotides to be 
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attached (http://www.roche-applied-science.com/fst/apoptosis.htm?/sis/apoptosis/ 
products/insitu_celldeath _detection.htm). 
 
4.2 Materials & Methods 
 
4.2.1 Chemicals & Reagents 
The In situ Cell Death Detection Kit, POD, DNase and Proteinase K were purchased from Roche 
Diagnostics, Mannhein, Germany.  DHEA and Aminopropyltriethoxysilane (APES) were purchased 
from Sigma Chemicals Co, St Louis, MO, USA.  Shandon Histoplast Wax was purchased from 
Lasec, South Africa.  DHEA was prepared in 10% ethanol in ethyl oleate (vehicle) and QA was 
dissolved in PBS. 
 
4.2.2 Animals 
Animals were maintained as described in Appendix A: Animal Care.  Animals were subjected to the 
same treatment regimen as described in Section 2.4.1.3.  To summarise, the dosing regimen is 
provided in Table 4.1. 
 
Table 4.1 Dosing regimen for apoptotic cell death detection. 
Group Name Daily Subcutaneous Injection Bilateral Intrahippocampal Injection on Day 8
Control Vehicle PBS 
Toxin Vehicle 120nmol Quinolinic acid 
5mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
10mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
20mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
 
4.2.3 Histological techniques for apoptosis detection 
 
4.2.3.1 Brain fixation 
After treatment, rats were sacrificed by cervical dislocation as laid out in Chapter 2: Lipid 
Peroxidation Investigation.  The brains were carefully removed and placed in Davidson’s fixative 
solution for 48 hours to prevent autolysis and bacterial destruction of the morphological 
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characteristics of the tissue.  This is accomplished by various stabilizing or cross linking agents such 
as formalin, methanol and Boiun’s reagent (Negoescu et al, 1998).  No universal fixative exists; 
rather one must be selected based on planned use of fixed tissue as well as economic factors.  The 
type and fixation of a tissue influence staining.  Negoescu et al (1997) demonstrated that formalin 
produced favourable results with TUNEL staining compared with other fixatives such as methanol.  
Fixation should occur rapidly to reduce manipulation which may result in histological artifacts.  
Davidson’s fixative acts quickly, producing good nuclear detail with minimal formalin pigment (Moore 
et al, 1953). 
The brains were then transferred to 70% ethanol for storage until use. 
 
Table 4.2  Davidson’s Fixing Reagent 
Volume (ml) Reagent Duration  
335 Water 
330 Ethanol 
220 Formaldehyde 
115 Glacial Acetic Acid 
48 hours 
 
4.2.3.2 Dehydration, Clearing and Waxing Process 
Before embedding of brains in wax can take place, the tissue to be embedded must be dehydrated.  
This is accomplished by immersing brains in increasingly concentrated alcohol solutions, followed by 
organic solvents to ensure all water is displaced from the tissue.  The protocol, a modified method of 
Geiger (1997), is laid out in Table 4.3 below.  The graded ethanol solutions remove moisture from the 
tissue and the clearing steps replace ethanol with chloroform.  The wax is then allowed to penetrate 
the tissue and eliminate the chloroform.  Vacuuming of the wax in the waxing step (Step 11 in Table 
4.3 below) ensures that the wax penetrates the tissue and that no air bubbles are present, which may 
adversely affect the slicing of the tissue. 
The process is more complex than used for other histology protocols since the TUNEL technique is 
more sensitive, and all reagents which may affect the fluorescence must be avoided.  Prior to 
dehydration, a 2mm wide section of the brain was removed to exclude the site of physical damage 
caused by the needle during surgery.  This is identifiable by a slight dimpling of the surface of the 
brain. 
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Table 4.3 The table indicates the solutions utilised, as well as the appropriate duration of 
immersion, for embedding brains in paraffin wax for apoptosis detection.  
Step Processing Agent Repeat X Time (Hrs) 
1  Dehydration 50% Ethanol 1 x 2 
2 70% Ethanol 1 x 2 
3 80% Ethanol 1 x 2 
4 90% Ethanol 1 x 2 
5 96% Ethanol 2 x 2 
6 Absolute Ethanol 3 x 2 
7   Clearing Absolute Ethanol: Chloroform 1 x 2 
8 Chloroform 1 x 2 
9 Xylene: Chloroform @ 60°C 1 x 1 
10  Waxing Melted Paraffin Wax (57-58°C 
mp) @ 60°C 
1 x 1 
11 Vacuum @ 60°C 15min 
12 Melted Paraffin Wax (57-58°C 
mp) @ 60°C 
2 x 1 
13  Embedding In molten wax @ 45°C Overnight 
 
4.2.3.3 Embedding 
The embedded sections of brain were affixed to wooden blocks and the blocks of wax were shaped 
using a hot blade so that the base of the wax block formed a rhombus, with the two converging sides 
leaving 2mm of wax surrounding the section of brain.  This is graphically represented below in Fig 
4.3.  Tissues may then be stored indefinitely without visible influence on the quality of TUNEL 
(Geiger, 1997). 
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Fig 4.2 Stylistic representation of a section of brain embedded in wax and mounted on a block 
before sectioning. 
 
4.2.3.4 Treating Slides 
Sectons were mounted on slides coated with APES (aminopropyl triethoxysilane).  Poly-L-lysine may 
also be used, but APES has been demonstrated to be superior in preventing tissue detachment from 
glass (Ben-sasson et al, 1995).  The selection of appropriate adhesive is vital, since the procedure 
for TUNEL staining involves multiple washing steps and the loss of tissue is a possibility with an 
unsuitable adhesive. 
 
Slides were coated with APES two days prior to use according to the method of Herrington and 
McGee (1992).  The slides were immersed in 2% Decon 90 (prepared in distilled water, warmed to 
60°C) for 30 minutes, then rinsed twice in distilled water and twice in acetone.  Slides were then air 
dried at 37°C.  Immersion in 2% APES in acetone for 30 minutes was followed by rinsing twice in 
acetone and then finally distilled water.  The slides were air dried at 37°C once again and stored in a 
cool, dry place.  
 
 
 
      Wax block 
              Brain 
Wooden block 
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4.2.3.5 Sectioning 
Sections were cut from the mounted block using a rotary microtome.  A microtome is a specialised 
piece of equipment consisting of an extremely sharp blade held in position and a chuck which is used 
to hold the block of wax upon which the tissue is mounted.  An oscillating mechanism is then utilised 
to move the chuck up vertically, moving it closer to the blade by a fixed distance with each oscillation 
(Hodgson, 1992).  The microtome was set to slice sections of 5μm thickness.  The shape of the wax 
block ensured that successive slices would form a ribbon of wax. 
The block was sliced and sections discarded until the hippocampus was reached.  When a ribbon of 
sections containing hippocampal slices was produced, the ribbon was transferred to a water bath set 
at 40°C using an artist’s fine paintbrush.  The warm water allows the wax ribbon to flatten out, which 
facilitates the transfer to slides. 
Once ribbons were sufficiently flattened, sections were transferred to slides previously prepared in 
Section 4.2.3.4.  The slides were placed on a warming tray to allow water to evapourate, and then 
placed in an oven set at 45°C overnight to allow the tissue to adhere properly to the slide.  
 
4.2.3.6 Deparaffinising Sections 
Since the TUNEL stain is aqueous, slices must be dewaxed and rehydrated before the reaction can 
proceed.  This is accomplished first by heat, then immersion of slides in xylene, followed by ethanol 
as detailed below in Table 4.4. 
 
Table 4.4 Dewaxing and rehydration protocol for brain tissue sections. 
Step Processing Agent Repeat X Time (min) 
1  Dewaxing Heating at 60°C 20 
2 Xylene 2 X 5 
3 Rehydrating Absolute Ethanol 2 X 3 
4 95% Ethanol 1 X 3 
5 90% Ethanol 1 X 3 
6 80% Ethanol 1 X 3 
7 70% Ethanol 1 X 3 
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4.2.3.7 Detection of Apoptotic Cells using TUNEL 
Apoptotic cells were identified by treating sections of brain with the Roche In Situ Cell Detection Kit, 
according to instructions found in the manual at www.roche-applied-science.com/pack-
insert/1684817a.pdf.  The Roche kit is highly sensitive, produces the best signal-to-background ratio 
and is user-friendly when compared with existing lab protocols and other detection kits (Negoescu et 
al, 1998).    
 
Slides previously deparaffinised were rinsed twice in PBS.  In order to ensure access to DNA in the 
nucleus, Proteinase K (20 μg/ml in 10mM Tris-HCl, pH 7.4-8) was added to tissue and slides were 
incubated at 37°C in a humidified chamber for fifteen minutes.  Proteinase K accomplishes this by 
digesting cross-linked proteins which increases cell permeability.  This concentration is optimised to 
prevent tissue damage and reduce the possibility of non-specific staining.  During this incubation and 
all subsequent incubations Parafilm® was placed over slides to prevent dehydration.  This step also 
ensures that the reaction mixture is evenly distributed over the entire section.  The reaction was 
terminated by washing thrice in PBS. 
 
Positive and negative controls were prepared due to differences in TUNEL detection between 
experimental runs.  One positive control was prepared by removing a slide pre-treated with 
Proteinase K as above and treating it with DNase I (3000U/ml in 50mM Tris-HCl, pH 7.4, containing 
1mg/ml BSA) and incubating for ten minutes at 25°C, then washing thoroughly with PBS.  The 
DNAse I is an endonuclease (Minnock et al, 1999) which hydrolyses sites adjacent to pyrimidine, 
resulting in intensive labelling of all nuclei.  It was prepared immediately before use as thawing from 
frozen results in inactivation of the compound. 
 
The TUNEL reaction mixture was prepared during the incubation time of the step described above 
and maintained in a dark environment since mixing of the components results in a light sensitive 
solution.  The reaction mixture was kept on ice during labelling.  Firstly, 100μl of the labelling solution 
from Vial 2 (a nucleotide mixture in reaction buffer) was removed to use on the negative controls.  
The balance of Vial 2 was subsequently combined with the enzyme solution in Vial 1.  This enzyme 
solution is terminal deoxynucleotidyl transferase (Tdt) from calf thymus (recombinant in E. coli) in a 
storage buffer.  
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4.2.3.8 TUNEL Labelling  
 
 
Fig 4.3 The diagram summarises the steps explained in Sections 4.2.3.5 to 4.2.3.9.  The 
diagram demonstrates an extra step whereby the fluorescence can be converted using a 
substrate to visualise apoptotic bodies with light microscopy (http://www.roche-applied-
science.com/fst/apoptosis.htm?/sis/apoptosis/products/insitu_celldeath _detection.htm).  
 
TUNEL reaction mixture (50μl) was added to each test section, as well as to the positive control 
slides which had been pre-treated in Section 4.2.3.7 with DNase I.  The negative control received 
50μl of pure labelling solution.  All slides were placed in a humidified chamber at 37°C for one hour 
for the end-labelling to occur.  The temperature may not increase above this value as temperatures 
over 40°C inactivate the enzyme (Geiger, 1997).  After one hour, slides were immersed in PBS and 
then washed thrice in PBS to ensure termination of the reaction. 
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4.2.3.9 Microscopy 
Prior to viewing slides, coverslips must be placed over the tissue to improve visibility and prevent 
damage.  This was accomplished by first adding sufficient SHUR/MOUNT ™, an aqueous mountant, 
to each slide and then gently lowering a coverslip into place.  Photomicrographs were immediately 
taken using an Olympus digital camera attached to a fluorescent detector at 200X magnification.  The 
fluorescence of the apoptotic cells is detected in the range 515-565nm which is why the 
photomicrographs appear green.  Sections were protected from light during viewing and 
photomicroscopy. 
 
4.3 Results 
The figures below are photomicrographs of brain tissue from rats treated as outlined above in Section 
4.2.2, and treated with the TUNEL stain. 
 
 
Fig 4.4 The photomicrograph is the positive control.  Hippocampal tissue was treated with 
DNAse I prior to TUNEL staining, which induced extensive DNA fragmentation and thus 
widespread fluorescent labeling (magnification X 200). 
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Fig 4.5 The photomicrograph of hippocampal tissue of rat receiving daily subcutaneous 
injections of the vehicle (10% ethanol in ethyl oleate).  The intrahippocampal injection 
contained PBS alone (magnification X 200). 
 
 
Fig 4.6 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of the vehicle (10% ethanol in ethyl oleate).  The intrahippocampal injection 
contained 120nmol QA (magnification X 200). 
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Fig 4.7 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 5mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained 120nmol QA (magnification X 200). 
 
 
 
Fig 4.8 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 10mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained 120nmol QA (magnification X 200). 
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Fig 4.9 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 20mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained 120nmol QA (magnification X 200). 
 
The following images are from brain tissue of rats which received 5mg/kg, 10mg/kg and 20mg/kg 
DHEA subcutaneously daily as above in Section 4.2.2.  These rats were sham-operated and were 
not exposed to neurochemical insult intrahippocampally. 
 
 
 
Fig 4.10 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 5mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained PBS alone (magnification X 200). 
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Fig 4.11 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 10mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained PBS alone (magnification X 200). 
 
 
 
Fig 4.12 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 20mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained PBS alone (magnification X 200). 
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4.4 Discussion 
DNase I controls confirm that staining on the experimental slides is in fact positive staining for 
apoptosis and not artifact.  DNase I results in intensive labeling of all nuclei throughout the tissue 
section. 
 
It is evident from the images above that there is reduced fluorescence – and therefore reduced 
evidence of apoptosis – in all rats treated with DHEA.  Even the lowest concentration of DHEA 
(5mg/kg) showed a remarkable decrease in the degree of apoptosis caused by intrahippocampal 
chemical insult by the neurotoxin QA.  QA has been shown to induce apoptosis (Cammer, 2001). 
 
The control group shows normal brain tissue with scattered fluorescent objects indicating several 
apoptotic cells as expected.  Fig 4.6 is taken from the toxin group which received intrahippocampal 
QA injections.  Fluorescence – and therefore apoptotic cell death – is widespread throughout the 
tissue due to the presence of the neurotoxin. 
 
DHEA itself does not induce apoptosis, due to the lack of neurons which appear to be stained green 
in Figs 4.9-4.11.  This is supported by Kaper and Mueller (1999) who demonstrated that DHEA alone 
has no effect on spontaneous apoptosis.  The figures demonstrate that at these concentrations, 
DHEA does not exert a pro-oxidant effect.  Mastracola et al (2003) showed that DHEA may act as 
pro-oxidant at high tissue concentrations, although many texts show that DHEA has neuroprotective 
properties (Bastianetto et al, 1998; Kimonides et al, 1997). 
 
The photomicrographs show that the neurosteroid protects against QA-induced apoptosis.  Slices of 
brain tissue from rats receiving each of the three doses of DHEA (5mg/kg, 10mg/kg and 20mg/kg) 
show a marked reduction in fluorescence, confirming that DHEA at all concentrations has protected 
the neural tissue from chemical injury by the neurotoxin.  
 
There is no visible difference between tissue from control brains and brains subjected to QA and 
various concentrations of DHEA, suggesting that DHEA prevents the induction of apoptosis by QA, 
and not merely reducing it. 
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These results are supported by Zhang et al (2002) who showed that DHEA suppresses apoptosis in 
cell culture by activating the serine-threonine protein kinase Akt.  These authors also noted that the 
sulphate ester inhibits the levels of Akt, increasing apoptosis.  The authors suggest that the 
equilibrium between DHEA and DHEAS regulates the survival of neural precursors during 
development of the CNS through this Akt signaling pathway (Zhang et al, 2002).  DHEA(S) was 
shown to decrease staurosporine-induced apoptosis in human peripheral blood lymphocytes 
(Takahashi et al, 2004).  Additionally, the authors demonstrated it was not mediated via androgen or 
oestrogen receptors.  DHEA has been demonstrated to markedly reduce cyproterone acetate-
induced apoptosis in rat hepatocytes (Kasper & Mueller, 1999). 
 
It can be observed from the above that apoptosis is reduced relative to the control section in the 
brains of rats treated with DHEA before a chemical insult to the hippocampus. 
 
Necrosis results in clusters of neighbouring cells.  This is associated with the inflammatory process 
as immune cells infiltrate the area and disrupt the tissue.  Apoptotic cells, however, are scattered or 
display a distinct pattern of distribution. 
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Histology 
 
5.1 Introduction 
Although assays such as those for lipid peroxidation and superoxide anion generation are 
important for determining molecular conditions, there is value in observing the influence of DHEA 
and quinolinic acid at various concentrations on the morphology of cells.  The preceding chapter 
has already demonstrated that DHEA ameliorates QA-induced apoptotic cell death in the rat brain 
and this chapter will investigate whether DHEA administration results in any change to the 
morphology of neural cells. 
 
Histology is literally the study of tissues and is the origin of much of the scientific knowledge of 
internal structure and tissues (Hodgson & Bernard, 1992).  There are many options for staining 
tissue, ranging from the cresyl violet stain which is a basic aniline dye, to immunohistochemical 
techniques which utilise antibodies such as TUNEL, used in the previous chapter.  
The Nissl stain is appropriate in this situation, as neurons are well visualised and any alterations in 
morphology can be easily identified.  The stain was named after Franz Nissl (1860-1919), a 
German neuropathologist and psychiatrist, as well as a close colleague of Alois Alzheimer. 
 
Cresyl violet is used to stain Nissl substances, primarily composed of rough endoplasmic reticulum 
and nuclei.  These substances are usually stained a dark blue or purple, depending on the protocol 
and neuronal morphology is thus easily visualised (Bauer, 1974).  
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5.2 Materials & Methods 
 
5.2.1 Chemicals & Reagents 
Quinolinic acid and DHEA were purchased from Sigma Chemical Company, Missouri.  DPX was 
purchased from Philip Harris Ltd, England and Haupt’s adhesive was prepared from 1g gelatine, 
100ml water, 15ml glycerol and 2g phenol, added as a preservative.  Cresyl violet was obtained 
from BDH Chemicals Ltd, England.  Shandon Histoplast Wax was purchased from Lasec, South 
Africa.  DHEA was prepared in 10% ethanol in ethyl oleate (vehicle) and QA was dissolved in PBS. 
All other chemicals and reagents were obtained locally and were of the highest quality available. 
 
5.2.2 Animals 
Animals were maintained as described in Appendix A: Animal Care.  Animals were subjected to the 
same treatment regimen as described in Section 2.4.1.3.  To summarise, the dosing regimen is 
provided in Table 5.1 below. 
 
Table 5.1 Dosing regimen for histological investigation. 
Group Name Daily Subcutaneous Injection Bilateral Intrahippocampal Injection on Day 8
Control Vehicle PBS 
Toxin Vehicle 120nmol Quinolinic acid 
5mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
10mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
20mg/kg DHEA in Vehicle 120nmol Quinolinic acid 
 
5.2.3 Histological Techniques 
 
5.2.3.1 Brain Fixation 
Since neural issues are extremely fragile and easily susceptible to rapid anoxic and postmortem 
changes (Chang, 1995), whole rat brains were immediately immersed in Davidson’s fixative for 48 
hours as detailed in Section 4.2.3.1.  The brains were then transferred to 70% ethanol for storage 
until further use. 
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5.2.3.2 Dehydration, Clearing and Waxing Process 
Brains were embedded in wax for preservation and ease of sectioning as described in the previous 
chapter and laid out in Table 5.2 below.  
 
Table 5.2 The table indicates the solutions utilised, as well as the appropriate duration of 
immersion, for embedding brains in paraffin wax for histological examination 
 
 
5.2.3.3 Embedding 
Brains embedded in wax were mounted onto wooden blocks and shaped as described in Section 
4.2.3.2. 
 
 
 
Step Processing Agent Repeat X Time (Hrs) 
1  Dehydration 50% Ethanol 1 x 2 
2 70% Ethanol 1 x 2 
3 80% Ethanol 1 x 2 
4 90% Ethanol 1 x 2 
5 96% Ethanol 2 x 2 
6 Absolute Ethanol 3 x 2 
7   Clearing Absolute Ethanol: Chloroform 1 x 2 
8 Chloroform 1 x 2 
9 Xylene: Chloroform @ 60°C 1 x 1 
10  Waxing Melted Paraffin Wax (57-58°C 
mp) @ 60°C 
1 x 1 
11 Vacuum @ 60°C 15min 
12 Melted Paraffin Wax (57-58°C 
mp) @ 60°C 
2 x 1 
13  Embedding In molten wax @ 45°C Overnight 
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5.2.3.4 Sectioning 
Sectioning was carried out as described in Section 4.2.3.5, with a slight modification.  As 
mentioned above, the cresyl violet stain is a more robust technique than the TUNEL stain used in 
Chapter 4: Apoptosis, making the use of APES as a tissue adherent unnecessary.  Haupt’s 
adhesive is used instead.  Sections of 5μm thickness were sliced into ribbons using a rotary 
microtome and placed into the water bath as described in Section 4.2.3.5.   
 
The slides were painted with a fine layer of freshly prepared Haupt’s adhesive before transferring 
sufficiently flattened ribbons of sections to slides.  The slides were placed on a warming tray to 
allow water to evapourate, and then placed in an oven set at 45°C overnight to allow the tissue to 
adhere properly to the slide.  
  
5.2.3.5 Deparaffinising Sections 
As with the TUNEL stain used in Chapter 4: Apoptosis, the cresyl violet stain is hydrophilic.  
Consequently the tissue must first be dewaxed and rehydrated, reversing the entire embedding 
process required prior to sectioning.  Due to the more robust nature of the stain as previously 
mentioned, an abbreviated dewaxing and rehydration protocol may be utilised.  The paraffin was 
removed by running slides through xylene twice, followed by immersion in a mixture of equal parts 
of xylene and ethanol.  Slides were then rinsed in ethanol and replaced in absolute ethanol 
overnight, as laid out in Table 5.3 below, before proceeding with cresyl violet staining. 
 
Table 5.3  Dewaxing and rehydration protocol prior to Nissl staining. 
Solvent Duration 
Xylene 5min X 2 
Xylene:Ethanol 3min 
Absolute Ethanol 5min 
Absolute Ethanol Overnight at 30°C
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5.2.3.6 The Cresyl Violet Stain 
The sections were Nissl stained using cresyl violet.  This stains the Nissl substances intense purple 
and the nuclei purple, while leaving the background clear (Bauer, 1974). 
 
Slides were removed from the absolute alcohol and placed in 0.1% cresyl violet solution for 2 
hours.  The solution was prepared from 0.25g cresyl violet, 0.0512g sodium acetate, 0.75ml glacial 
acetic acid and 250ml MilliQ water.  The solution was corrected to pH 3.5 and filtered.  Slides were 
removed from the cresyl violet stain and were rapidly differentiated in 95% ethanol by rinsing in a 
flat dish until the background was clear.  The sections were then dehydrated as laid out in Table 
5.4 below. 
 
Table 5.4 Dehydration protocol for Nissl stained sections. 
Solvent Duration 
Absolute Ethanol 5min X 2 
Xylene 5min X 2 
 
5.2.3.7 Microscopy 
Prior to viewing slides, coverslips must be placed over the tissue to improve visibility and prevent 
damage.  This was accomplished by first adding sufficient of the mountant, DPX, to each slide 
which had been kept moist with a small aliquot of xylene.  Coverslips were then gently lowered into 
place.  The slides were allowed to dry for 48 hours on a flat surface before viewing. 
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5.3 Results  
All slides were viewed at 400 X magnification using a light microscope and images were captured 
with an Olympus digital camera. 
 
 
Fig 5.1 The photomicrograph of hippocampal tissue of rat receiving daily subcutaneous 
injections of the vehicle (10% ethanol in ethyl oleate).  The intrahippocampal injection 
contained PBS alone (magnification X 400). 
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Fig 5.2 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of the vehicle (10% ethanol in ethyl oleate).  The intrahippocampal injection 
contained 120nmol QA (magnification X 400). 
 
 
Fig 5.3 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 5mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained 120nmol QA (magnification X 400). 
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Fig 5.4 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 10mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained 120nmol QA (magnification X 400). 
 
 
Fig 5.5 The photomicrograph is of the hippocampal tissue of rat receiving daily subcutaneous 
injections of 20mg/kg DHEA in the vehicle (10% ethanol in ethyl oleate).  The 
intrahippocampal injection contained 120nmol QA (magnification X 400). 
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5.4 Discussion 
The cells of Ammon’s Horn have distinct pyramidal morphology which is altered with the 
introduction of a neurotoxin such as QA (Southgate, 1998).  The cell bodies appear to be damaged 
which is characteristic of toxicity. 
 
QA is an NMDA agonist as mentioned in Section 1.3.1 and causes damage by overstimulation of 
this receptor, resulting in increased cytosolic Ca2+ levels and eventual cell death (Santamaría et al, 
2003).  Thus, neurons damaged by QA typically exhibit swelling, alteration in the typical pyramidal 
morphology of hippocampal neurons and loss of cell integrity. 
 
The results show that DHEA is protective of hippocampal neurons when administered according 
the above treatment regimen (see Table 5.1).  Fig 5.2 shows hippocampal cells subjected to the 
neurotoxin QA with no subcutaneously administered DHEA.  The cells do not display typical 
healthy morphology as exhibited in Fig 5.1 as QA causes significant damage and 
neurodegeneration, possibly due to a combination of osmotic changes and free radical damage, as 
discussed previously.  
 
It is clear from the above photomicrographs (Figs 5.3 to 5.5) that DHEA has a beneficial effect on 
cell integrity, preserving the morphology of the cell in the presence of the NMDA agonist.  These 
results are supported by Chapter 2: Lipid Peroxidation Investigation which demonstrated that 
DHEA reduced QA-induced lipid peroxidation, and thus cell membrane damage, in the 
hippocampus.  These results are also in keeping with other investigations which demonstrated that 
other important and structurally similar hormones such as oestrogen and progesterone had 
similarly favourable effects on neural cells (Tomas-Camardiel et al, 2002; Garcia-Segura et al, 
2003; Schumacher et al, 2003).  
 
This concurs with the evidence provided in the previous chapter that DHEA had a beneficial effect 
on the induction of apoptosis by QA, reducing the apparent incidence of this type of programmed 
cell death. 
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DHEA could be protecting hippocampal neurons in several ways including inhibiting the production 
of free radicals, stabilisation of membranes or interacting with QA or one of its mediators. 
Since DHEA(S) concentrations are minimal in rodents and can be considered naïve of endogenous 
DHEA (Baulieu, 1996), it is unlikely that this prevention of the harmful effects of DHEA is in fact 
due to the metabolic products of this hormone.  However, further examination is required before 
this can be conclusively stated.  
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Pineal Organ Culture Studies 
 
6.1 Introduction 
Organ culture is a technique pioneered in 1926 in the Strangeways Laboratory in Cambridge 
(Strangeways & Fell, 1926).  More than three quarters of a century later it is still a relatively simple 
yet effective technique for determining the effects of exogenous compounds on the endogenous 
synthesis of pineal indoleamines.  Modifications to this technique have improved its scope 
immensely, from the initial observation of the growth of chick cartilage and eyes by Strangeways 
and Fell (Wilson, 2005) to the ability to keep fully differentiated organs alive while preventing their 
growth or further differentiation.  The pineal gland in organ culture is able to remain viable for six 
days under optimal conditions, during which period it maintains it metabolic functions and can 
utilise exogenous serotonin to produce pineal indoleamines (Daya et al, 1989).  As much as 95% of 
these synthesised indoles is secreted into the culture medium and may then be isolated and 
quantified. 
 
Pineal indole metabolism has been well documented and the effect of DHEA on this metabolism 
may be a key to its properties as a neuroprotectant.  The chief pineal hormone, melatonin, has 
been well-documented (Reiter et al, 1995) as a free radical scavenger and the effect of DHEA on 
its metabolism is of interest.  Melatonin’s antioxidant properties have resulted in the suggestion of a 
potential role in the prevention or alleviation of various neurological disorders. 
 
Fundamentally, pineal glands are incubated with radiolabelled serotonin for 24 hours, in the 
presence or absence of DHEA.  Thin Layer Chromatography (TLC) is utilised to separate the 
radiolabelled metabolites present in the culture medium and the amounts are determined using 
scintillometry.  
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Fig 6.1 The diagram indicates the various metabolic pathways in pineal indole metabolism 
(modified from Young and Silman, 1982). 
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6.2 Materials & Methods 
 
6.2.1 Chemicals & Reagents 
DHEA was obtained from Sigma Chemical Co, St Louis, USA.  14C Serotonin (specific activity: 
55mCi/mL) was obtained from Amersham International, England.  BGJb culture medium 
(composition shown below in Table 6.1) was obtained from Gibco, Europe and supplemented with 
the antibiotics streptomycin (0.1mg/L) and benzyl penicillin (100units/ml) (Hoechst, South Africa).  
The TLC plates (aluminium, coated with silica gel 60, Type F254 – 0.25mm) were purchased from 
Merck, Darmstadt, Germany.  Beckman Ready-Sol Scintillation fluid was purchased from Beckman 
RIIC Ltd, Scotland.  The indole standards HT, HA, HL, MA, ML, aMT, and aHT were purchased 
from Sigma Chemicals Co, St Louis, USA.  All other reagents and chemicals were obtained locally 
and were of the highest purity available. 
 
Table 6.1  Contents of the BGJb culture medium 
 
Compound Concentration (mg/litre) 
      
Amino Acids  
L-Alanine 250.0 
L-Arginine 175.0 
L-Aspartic acid 150.0 
L-Cysteine (HCL) 90.0 
L-Glutamine 200.0 
Glycine 800.0 
L-Histidine 150.0 
L-Isoleucine 30.0 
L-Leucine 50.0 
L-Lysine (HCL) 240.0 
L-Methionine 50.0 
L-Phenylalanine 50.0 
L-Proline 400.0 
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L-Serine 200.0 
L-Threonine 75.0 
L-Tryptophan 40.0 
DL-Valine 65.0 
  
Vitamins  
α-Tocopherol phosphate 1.0 
Ascorbic acid 50.0 
Biotin 0.2 
Calcium pantothenate 0.2 
Choline chloride 50.0 
Folic acid 0.2 
Inositol 0.2 
Para-aminobenzoic acid 2.0 
Pyridoxal phosphate 0.2 
Riboflavin 0.2 
Thiamine hydrochloride 4.0 
Vitamin B12 0.04 
  
Inorganic Salts  
Dihydrogen sodium ortho-phosphate 90.0 
Magnesium sulphate 200.0 
Potassium Chloride 400.0 
Potassium dihydrogen phosphate 160.0 
Sodium bicarbonate 3500.0 
Sodium chloride 5300.0 
  
Supplements  
L – Glutamine 200 
Streptomycin sulphate 0.1 
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Benzyl Penicillin 100 units/ml 
  
Other Compounds  
Calcium lactate 555.0 
Glucose 10000.0 
Other Compounds cont.  
Phenol red 20.0 
Sodium acetate 50.0 
 
 
6.2.2 Animals 
Male Wistar rats which had been cared for as laid out in Appendix A: Animal Care, weighing 
approximately 300g were randomly divided into two groups (n=5).  These rats were killed by 
cervical dislocation at approximately 11h00. 
 
6.2.3  Removal of Pineal Gland 
After killing, the pineal glands were removed from the rat brains by making incisions on both sides 
of the skull, reaching from the foramen magnum to the orbits.  The top of the skull was carefully 
lifted and the pineal gland exposed.  The pineal gland was isolated and all adhering tissue 
removed. 
 
6.2.4 Organ Culture 
The technique employed by Klein and Notides (1969) was modified to achieve separation of the 
radiolabelled indoleamines.  The pineal glands were immediately placed in sterile 75 x 10mm 
Kimble tubes containing 52μl of fortified BGJb culture medium.  In addition, these tubes contained 
either 5μl of the test solution of DHEA to produce the final desired concentration of 1 x 10 –5 M, or 
5μl of the vehicle of the test solution as a control group as shown below.  
Subsequently, 8μl of  14C Serotonin with a specific activity of 55mCi/mL was added to each tube, 
producing a total volume of 65μl. 
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Table 6.2  The composition of the liquid medium used in the Kimble tubes in control and DHEA-
treated samples. 
Control Volume Test 
BGJb Culture Medium 52μl BGJb Culture Medium 
Vehicle (absolute ethanol) 5μl DHEA test solution 
14C Serotonin 8μl 14C Serotonin 
 65μl  
 
 
The Kimble tubes were then saturated with carbogen (5% carbon dioxide in oxygen) and sealed, 
before incubating at 37°C in the dark for 24 hours in a Forma Scientific Model 3028 incubator. 
The reaction was halted by the removal of the pineal gland from the solution.  The medium was 
then frozen and stored at  -20°C until TLC analysis was performed. 
 
6.2.4.1 Spotting of the TLC Plates 
TLC plates first activated by heating them at 70°C for 1hour were spotted with culture medium and 
dried under a thin stream of nitrogen gas to prevent atmospheric oxidation of the metabolites and 
hasten drying.  The standard solution was prepared by adding 1mg of each of the seven 
indoleamines (HT, HA, HL, MA, ML, aMT, and aHT) to a solution of 95% ethanol, containing 1% 
ascorbic acid to prevent undesirable oxidation.  This standard solution was then delicately spotted 
over the culture medium and again dried under a thin stream of nitrogen.  The plates were spotted 
under subdued lights to prevent photooxidation of the indoleamines. 
 
6.2.4.2 Elution of the TLC Plates 
Two solvent systems were utilised, namely Solvent System A, consisting of 
chloroform:methanol:glacial acetic acid in a ratio of 93:7:1, and Solvent System B comprising ethyl 
acetate. 
 
The plate was eluted in the Solvent System A twice.  During each elution, the solvent front was 
allowed to develop a distance of 9cm, after which the plate was removed from the TLC tank and 
dried under a gentle stream of nitrogen, before the subsequent/second elution commenced.  The 
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plate was then turned at right angles (90°) to the first direction of development and eluted in 
Solvent System B.  Once again the plate was dried under nitrogen gas before visualizing the spots 
under UV light at 254nm.     
 
Fig 6.2    Diagrammatic representation of a TLC plate when visualised under UV light, showing 
separation of the indoleamines.  Each plate is eluted twice in the direction indicated as 
“Solvent System A”, then once more in the direction indicated as “Solvent System B” in 
order to achieve satisfactory separation of the standards MA, HA, ML, HL aMT and 
aHT. 
 
6.2.4.3 Determining the Radioactivity of Metabolites 
The spots were isolated from the plates and added to individual plastic scintillation vials.  Ethanol 
(1ml) and the scintillation cocktail (3ml) were added to each vial and after sealing, the vials were 
vortexed for thirty seconds to ensure the indoleamines were homogenously mixed with the solvent 
system, and did not remain on the TLC plate fragments. 
The radioactivity of each metabolite was determined using a Packard Tri-Carb scintillation counter, 
model number 2300TR. 
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6.2.4.4 Statistical Analysis 
All data was first analysed using ANOVA, followed by the Student-Newman-Keuls Multiple Range 
Test. Comparisons between mean values were significantly different if p values were <0.05 (Zar, 
1974). 
 
6.3 Results 
Results were expressed as counts per minute per 10 ųL per pineal gland, with n=5. 
Serotonin and methoxytryptamine do not migrate from the origin in this solvent system (Klein & 
Notides, 1969), thus results expressed are at the origin are for both these compounds. 
Good separation of the indole metabolites was achieved and high counts were obtained.  
Background counts were negligible. 
 
Table 6.3 The effect of in vitro DHEA supplementation on rat pineal indole metabolism.  * 
indicates a significant difference from the control with p<0.001 (Student-Newman-
Keuls Multiple Range Test).  
 
 
 
Mean ± SEM (n=5) 
Pineal Metabolite Control DHEA 
Melatonin (aMT) 141 ± 53 115 ± 57 
5-methoxytryptophol (ML) 136 ± 45 91 ± 40 
5-methoxyindoleacetic acid (MA) 52 ± 11 168 ± 34 
N-acetyl serotonin (aHT) 877 ± 269 3229 ± 867 * 
5-hydroxytryptophol (HL) 2284 ± 621 7229 ± 1593 
5-hydroxyindoleacetic acid (HA) 3269 ± 1046 11214 ± 2867 
Origin (HT/MT) 34221 ± 4450 41351 ± 9205 * 
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Fig 6.3 The effect of in vitro DHEA supplementation on rat pineal indole metabolism.  Results 
are expressed as percentage total count per minute per 10 μL per pineal gland.           
* indicates a significant difference from the control with p<0.001 (Student-Newman-
Keuls Multiple Range Test).  The x axis indicates the metabolite. 
 
The results show a significant (p<0.001) decrease in the amount of HT/MT in pineal glands 
incubated with DHEA compared with the control and a significant (p<0.001) increase in the 
production of N-acetyl serotonin.  There was no significant increase in the production of MA HL HA 
as well as no significant decrease in the production of the remaining metabolites, ML and 
melatonin. 
 
6.4 Discussion 
The rat pineal gland, when subjected to organ culture, metabolises radiolabelled serotonin to 
various pineal indoleamines.  The effect of an exogenous substance on this metabolism can then 
be assessed by comparing drug treated pineals to untreated ones.  
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From the above graph, it can be observed that while DHEA does have an impact on certain 
metabolites, there is no significant change in the synthesis of melatonin, a well-documented free 
radical scavenger and anti-oxidant.  These results concur with those of Djeridane and Touitou 
(2004), confirming that the neuroprotectant effect of DHEA, as outlined in Chapter 2: Lipid 
Peroxidation Investigation, is not due to an increase in the production of melatonin.  San Martin and 
Touitou (2000) previously demonstrated that DHEAS increased -adrenergic-stimulated melatonin 
secretion by rat pineals in vitro. 
 
The results show that the presence of DHEA results in a significant decrease in the amount of 
serotonin/methoxytryptamine, suggesting that the overall pineal indole metabolism is increased, 
leaving less substrate after 24 hours of organ culture.  This is plausible, since an increase in 
metabolism would not affect the relative amounts of metabolites produced. 
 
DHEA significantly increases the production of N-acetylserotonin, although a subsequent increase 
in the amount of melatonin synthesised is not evident.  This indicates that while more serotonin is 
converted to N-acetylserotonin via N-acetyltransferase (NAT), DHEA does not cause an increase in 
the activity of hydroxyindole-O-methyltransferase (HIOMT).  This is supported by the fact that other 
metabolites relying on HIOMT for synthesis, namely 5-methoxytryptamine, 5-methoxyindole acetic 
acid and 5-methoxytryptophol, show no significant increase in production (see Fig 6.4).  Djeridane 
& Touitou (2004) showed that neither DHEA nor its sulphated derivative alter HIOMT over a range 
of acutely administered doses, while DHEAS results in increased melatonin production through 
increased activity of NAT.  This enzyme is in most circumstances the rate-limiting step in melatonin 
synthesis (Klein et al, 1997) and is subject to a circadian rhythm (Klein & Weller, 1970). 
 
Methods including drying spots under nitrogen gas, the addition of ascorbic acid to the standard 
solution, and subdued lighting were employed to minimise undesirable oxidation of the metabolites 
which could have affected results. 
 
These results are derived from an in vitro study and it needs to be determined whether the in vivo 
administration of DHEA would produce similar effects.  The question concerning the existence of 
an in vitro-in vivo correlation bears further investigation.
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Metal Interaction Studies 
 
7.1 Introduction 
Previously it has been established that DHEA is able to reduce QA-induced lipid peroxidation, as 
well as apoptosis and other structural damage.  Since the mechanism of action of DHEA is unclear, 
and metal ions have a well-established role in neurodegenerative processes (Bear et al, 2003) this 
chapter will explore the possibility that DHEA interacts with metal ions. 
Various techniques may be utilised in the characterisation of metal-ligand interactions including 
ultra-violet/visible (UV/VIS) spectroscopy, infrared (IR) spectroscopy, nuclear magnetic resonance 
(NMR) and electrochemistry.  
 
Since the mechanism of action of DHEA with regard to neuroprotection is largely unknown, and 
metal ions are known to be important  in the generation of free radicals, the investigation of a 
possible interaction between DHEA and two biologically important ions, namely Cu(II) and Fe(III) 
was conducted.  Two methods were employed.  Firstly, a UV/VIS spectroscopic study was 
performed to determine if an interaction was occurring, then these results were confirmed and 
expanded upon through an electrochemical investigation.  
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7.2 Characterisation of Metal-Ligand Interaction Using UV/VIS Spectroscopy 
 
7.2.1 Materials & Methods  
 
7.2.1.1 Chemicals & Reagents 
DHEA was obtained from Sigma Chemicals Co, St Louis, USA.  Iron chloride and copper chloride 
were purchased from Merck, Midrand, South Africa.  DHEA was dissolved in 30% ethanol due to its 
poor aqueous solubility.  All reagents were prepared in de-aerated MilliQ water unless otherwise 
noted.  All other chemicals and reagents were obtained locally and were of the highest quality 
available. 
 
7.2.1.2 UV/VIS Spectroscopy 
Spectroscopic analyses are based on the theory that compounds posses the ability to absorb 
electromagnetic radiation at specific wavelengths.  Since all compounds containing alternating 
double and single bonds will absorb UV radiation, and all coloured compounds absorb visible 
radiation, UV/VIS spectroscopy can be widely utilised.  These absorption spectra are characteristic 
and any alteration in the structure or composition of a compound will result in a change in the 
spectrum of that compound, usually by a shift in wavelength or a change in extinction coefficient of 
the absorbance (Newman, 1969).  By analysing the absorption spectrum of DHEA alone in 
solution, as well as the effect of adding increasing concentrations of metal ion, the interaction 
between DHEA and the two metals under investigation can be characterised.  A range of 
concentrations of DHEA and metal were investigated from 1 x 10-3 M to 1 x 10-6 M.  Samples were 
analysed using a GBC UV/VIS 916 spectrophotometric detector.  
 
7.2.2 Results 
The results are summarised below in Table 7.1.  The lambda max for DHEA is 292.4nm.  At the 
DHEA-Fe(III) ratio of 1:1, the peak height shifts to a shorter wavelength of 288.40nm.  At the 
DHEA-Fe(III) ratio of 10:1, the peak wavelength is 289.2nm and at concentrations above 10:1, the 
peak wavelength shifts to 290nm and remains constant.  The absorbance demonstrates a slight 
increase, but this change is not sufficient to be significant.  This trend is repeated for DHEA-Cu(II) 
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experiment where above 10:1 the peak wavelength shifts to 292.4nm and remains constant for 
higher ratios.  
 
Table 7.1 The table shows the relative concentrations of DHEA and metal ions, as well as the 
effect on peak height in terms of wavelength and absorbance. 
Concentration of 
DHEA (mM) 
Concentration of metal 
(mM) 
Peak height 
(Absorbance) 
Peak Wavelength 
(nm) 
 Fe(III)   
1 1 0.961 288.4 
10 1 0.387 289.2 
100 1 0.670 290.0 
 Cu(II)   
1 1 0.853 291.1 
10 1 0.701 290.0 
100 1 0.614 290.0 
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Fig 7.1 The graph shows the reduction in peak height and the shift to shorter wavelengths of 
DHEA upon the addition of Fe(III). 
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Fig 7.2 The graph shows the reduction in peak height and the shift to shorter wavelengths of 
DHEA upon the addition of Cu(III), although at ratios above 10:1, there is no further 
shift in wavelength. 
 
7.2.3 Discussion 
When DHEA and Fe(III) are present in equimolar amounts, there is a distinct blue shift, although 
the reduction in absorbance is not marked.  When the concentration of DHEA exceeds the 
concentration of Fe(III) by a factor of ten, this shift to a shorter wavelength of radiation is still 
evident.  The reduction in absorbance and the peak shift to shorter wavelengths displayed by 
DHEA in the presence of Fe(III), as well as the presence of Cu(II) may be indicative of a weak 
metal-ligand interaction.  Electrochemical investigations as detailed below will further examine the 
hypothesis that DHEA may have a weak interaction with Cu(II) and Fe(III).  
290
292.4
290
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7.3 Characterisation of Metal-Ligand Interaction Using Electrochemistry 
 
7.3.1 Materials & Methods 
 
7.3.1.1 Chemicals & Reagents 
DHEA was obtained from Sigma Chemicals Co, St Louis, USA.  Iron chloride and copper chloride 
were purchased from Merck, Midrand, South Africa.  DHEA was dissolved in 30% ethanol in MilliQ 
water.  Tris-HCl was used to prepare a buffer of pH 7.4.with 30% ethanol.  All reagents were 
prepared in de-aerated Milli-Q water unless otherwise noted.  All other chemicals and reagents 
were obtained locally and were of the highest quality available. 
 
7.3.1.2  Electrochemistry 
Electrochemistry has been used successfully in several metal-ligand investigations including those 
using endogenous molecules as ligands (Limson et al, 1998; Limson & Nyokong, 1997; Lack & 
Nyokong, 2001).  The investigation of electrochemical interactions was conducted in this study 
using an electrochemical cell comprising three electrodes, illustrated in Fig 7.3 below.   
 
 
Fig 7.3 A diagrammatic representation of the cell used in electrochemical analyses, showing 
the reference, working and auxiliary electrodes (Limson, 1998). 
 
The primary electrode is the reference electrode against which the potential of the working 
electrode is measured.  The reference electrode maintains a constant potential and is isolated.  
Various reference electrodes exist including the hydrogen electrode, smooth platinum electrode, 
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saturated calomel electrode, glass electrode and the silver/silver chloride electrode.  The 
silver/silver chloride (Ag/AgCl) electrode is particularly useful in aqueous solutions and comprises a 
silver wire anodised with silver chloride.  The wire is encased in a glass tube containing 
concentrated solutions of AgCl and a chloride salt, usually potassium or sodium.  The electrode is 
protected from solution by the semi-permeable salt bridge (Sole, 1995; Hawkridge, 1996). 
The auxiliary electrode is constructed of an inert metal such as platinum, mercury or gold 
(Glasstone, 1942).  It prevents voltage drop across the working and reference electrodes.  Glassy 
carbon electodes (GCE) are frequently utilised as working electrodes since they posess suitable 
mechanical and electrical properties.  They are chemically inert, have a low electrical resistance 
and performance is reproducible.  It is at the working electrode that the analyte undergoes 
oxidation and reduction.  
 
Two types of scans are frequently employed to asses the electrochemical activity of compounds.  
These are adsorptive stripping and cyclic voltammetry.  Both are obtained from the same 
apparatus as described above.  Adsorptive stripping voltammetry (ASV) is a useful technique for 
assessing metal-ligand interactions since analytes tend to naturally pre-concentrate at an electrode 
and by polarising the electrode at a more negative potential than the reduction potential of the 
metal, this tendency is enhanced. 
 
 
  7: Metal Interaction Studies 
  105 
 
Fig 7.4 The diagram illustrates the adsorptive stripping voltammetric technique, including 
accumulation, deposition and stripping.  The equations show the reactions occurring at 
the electrode.  When a suitable chelating ligand (L) is added to a solution of electrolyte 
and metal analyte (M), metal-ligand (ML) complexation is facilitated and this complex 
is adsorbed at the electrode during the deposition time (Limson, 1998). 
 
A metal ion will result in a specific response at a given potential, providing a specific 
voltammogram.  The addition of a ligand facilitates the metal ion movement to the electrode, 
thereby changing the profile of the voltammogram.  An increase in current indicates affinity of the 
ligand toward the metal, while a decrease in current response may indicate competition between 
the ligand and analyte, or the formation of a strong metal-ligand bond which is not easily reduced.  
A negative potential shift is characteristic of a strong metal-ligand interaction, while a large positive 
shift is associated with a weak metal-ligand interaction (Limson et al, 1998; Lack & Nyokong, 
2001). 
 
Tris-HCl at pH 7.4 was used in the preparation of the cells which were made up with metal-ligand 
ratios from 1 to 6 (hereafter referred to as ML1 to ML6) and analysed electrochemically.  DHEA 
was prepared in 30% ethanol due to its poor aqueous solubility.  Nitrogen gas is bubbled through 
the cell prior to scanning to remove traces of oxygen, thus increasing the rate of evapouration of 
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the ethanol solution.  Evapouration efficiency may affect the reduction-oxidation of metal ions since 
these processes are a function of temperature.  Removal of oxygen using an inert gas is essential 
as oxygen is electroactive at most electrodes and may interfere with voltammetric and 
electrochemical measurements (Sawyer & Roberts, 1974).  Fresh cells were prepared prior to each 
scan in order to prevent loss of solvent which may have had an effect on the results.  
 
The Bio Analytical Systems CV-50W voltametric analyser and C2 cell stand were used to maintain 
a constant atmosphere (BAS, Indiana, USA).  The working, auxiliary and reference electrodes 
employed for  voltammetric investigations were the glassy carbon electrode (3mm), platinum wire 
and a silver/silver chloride [KCl = 3M] electrode, respectively.  The GCE was polished prior to each 
use with alumina on a Buehler pad, followed by rinsing with nitric acid and Milli-Q water.  The 
purging time, deposition potential and deposition time were kept constant for the adsorptive 
stripping voltammograms of each metal.  Voltammograms were scanned in the negative direction 
from the deposition potential to at least 0.5V beyond the reduction of the metal at a scan rate of 
0.10V.s-1 to strip the adsorbed species from the electrode.  During stripping, current responses to 
the reduction of the metal-ligand species were measured as a function of potential.  All potential 
values quoted are referenced against the Ag/AgCl reference electrode. 
 
7.3.2 Results 
 
7.3.2.1 Copper(II)-DHEA Investigation 
The figures show the decrease in current at the electrode (Fig 7.5) when the DHEA concentration 
is equal to the Cu(II) concentration (ML1) and when it is quadruple the metal concentration (ML4), 
as well as the shift to a slightly more negative potential (Fig 7.6).  Fig 7.7 combines these data to 
demonstrate that increasing concentrations of DHEA are exerting an effect on the profile of the 
voltammogram. 
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Fig 7.5 The graph shows the effect of increasing concentration of DHEA on the change in 
current in the electrochemical cell.  The troughs in the graph at ML1 and ML4 are 
indicative of an interaction with Cu(II).  
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Fig 7.6 The graph shows the effect of increasing concentration of DHEA on the shift in 
potential in the electrochemical cell.  The changes in the graph correspond with those 
in Fig 7.5 above. 
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Fig 7.7 The voltammogram illustrates the interaction between DHEA and Cu(II) in Tris-HCl, pH 
7.4.  Each line represents All cells contained 80μM Cu(II).  The DHEA concentration in 
each cell is 0μM (dark red), 200μM (dark blue), 400μM (dark green), 600μM (light 
green), 800μM (light red), 1000μM (magenta), 1200μM (light blue).  The copper 
concentration is 200μM throughout.  The baseline is represented by the dashed black 
line.  The vertical axis represents the current, while the horizontal axis shows the 
potential versus the Ag/AgCl electrode. 
 
7.3.2.2 Iron(III)-DHEA Investigation 
The figures below indicate at decrease in current (Fig 7.8) and a shift to a more negative potential 
on the addition of  DHEA (Fig 7.9) These data are combined in Fig 7.10 to illustrate the effect of  
increasing concentrations of DHEA on the profile of the voltammogram. 
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Fig 7.8 The graph shows the effect of increasing concentration of DHEA on the change in 
current in the electrochemical cell containing Fe(III).   
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Fig 7.9 The graph shows the effect of increasing concentration of DHEA on the shift in 
potential in the electrochemical cell.  The changes in the graph correspond with those 
in Fig 7.8 above. 
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In Fig 7.10 below the shift in potential is apparent from -0.32V for Fe(III) alone to -0.4V in the 
presence of equimolar DHEA.  There is little variation in potential for the increased concentrations 
of DHEA examined. 
 
Fig 7.10 The voltammogram illustrates the interaction between DHEA and Fe(III) in Tris-HCl, 
pH 7.4.  The DHEA concentration in each cell is 0μM (dark red), 80μM (dark blue), 
160μM (dark green), 240μM (light green), 320μM (light red), 400μM (magenta), 
480μM (light blue).  The Fe(III) concentration is 80μM throughout.  The baseline is 
represented by the dashed black line.  The vertical axis represents the current, while 
the horizontal axis shows the potential versus the Ag/AgCl electrode. 
 
7.3.3 Discussion 
The results show that DHEA, while not electrochemically active itself, is interacting with both metal 
ions examined.  A scan of DHEA alone shows the steroid exhibits no electrochemical activity up to 
concentration of 1 x 10-3M.  There is evidence of visible precipitation from 3 x 10-3 M. 
The addition of DHEA to Fe(III) results in a shift to more negative potential with a minimal change 
in peak height.  The peak observed for DHEA and Fe(III) at -0.4V suggests a metal ligand 
interaction since this potential is more negative than metal alone (Fig 7.10).  The reduction in peak 
and shift to more negative potential indicates Fe(III) is becoming more difficult to reduce, which is a 
function of ligand interaction.  Subsequent scans of increasing concentrations of DHEA show a 
successive shift to a more positive current.  This is an indication that the extent of interaction is not 
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marked, but that a weak interaction does exist.  Cu(II) exhibits a negligible shift in potential, but the 
successive shift to more positive current is still apparent.  This suggests that the affinity and 
strength of the interaction are both weak.   
 
It has been noted that the acidity of the solution, as well as the concentration of species under 
consideration will have an effect on potential (Butler, 1964).  Since any neuroprotective effects 
exerted by DHEA will occur at physiological pH, it is irrelevant to this investigation how DHEA may 
interact with metal ions at non-physiological pH.  In addition, chloride ions form fairly stable 
complexes with many metal ions so Burgess (1999) recommends avoiding hydrochloric acid in 
such investigations, but again, chloride ions are present physiologically. 
 
DHEA was able to reduce QA-induced lipid peroxidation in both in vitro and in vivo investigations.  
It has been suggested that the peroxidative effect of QA is mediated by metal ions, particularly iron 
(Stipêk et al, 1996).  Elevated levels of iron have been demonstrated in various neurodegenerative 
disorders, including AD, Parkinson’s disease, multiple system atrophy and progressive 
supranuclear palsy (Campbell, 2001).  The interaction of DHEA with Fe(III), albeit weak, may 
provide a clue to the unclear mechanism of action of DHEA, even though QA interacts with ferrous 
and not ferric ions.  Further investigation of the interaction of this steroid molecule with metal ions 
will be of value. 
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Summary 
 
Chapter 1 
 
This literature review provides a concise introduction to dehydroepiandrosterone and relevant 
theory relating to neuroscience.  Areas such as basic neuroanatomy were covered.  Neurotoxins 
such as cyanide and quinolinic acid were introduced and the theory of excitotoxicity was explored.  
The role of free radicals in the biological system was addressed and the chapter also covered how 
cell death occurs.  A brief discussion on neurodegeneration and neuroprotection was followed by a 
comprehensive review of dehydroepiandrosterone including known pharmacokinetics and 
pharmacology.  The concepts of neurosteroids and neuroactive steroids were introduced, before 
dealing with the mechanism of action of dehydroepiandrosterone. 
 
Chapter 2 
 
Quinolinic acid is well established as a neurotoxic substance and Chapter 2 illustrated the effect of 
quinolinic acid on rat brain homogenate.  Increasing concentrations of QA were shown to cause an 
increase in lipid peroxidation in a dose-dependent manner.  These results concur with previously 
reported findings. The effect of DHEA on QA-induced lipid peroxidation was investigated in both in 
vitro and in vivo models and the results show that DHEA reduces QA-induced lipid peroxidation.  
Data obtained in vivo does not suggest a dose-dependent decrease at the doses utilised, namely 
5mg/kg, 10mg/kg and 20mg/kg.  Thus the ability of a compound to reduce the degree of lipid 
peroxidation may indicate its value as a neuroprotectant.  
 
Chapter 3 
 
This chapter focusses specifically on the superoxide free radical and assessed the effect of various 
concentrations of DHEA on cyanide-induced superoxide anion generation.  The ability of cyanide to 
cause a dose-dependent increase in superoxide anion generation was confirmed and it was 
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observed that DHEA isunable to reduce the concentration dependent induction of superoxide 
radicals by KCN at the concentrations used.  Therefore, it is suggested that the neuroprotection 
provided by DHEA observed in other chapters is not mediated through the inhibition of the 
production of the superoxide anion, and another mechanism of action must exist. 
 
Chapter 4 
 
Apoptosis, a form of programmed cell death, was initiated with QA while rats received one daily 
subcutaneous injection of DHEA, at three different doses over two weeks.  Hippocampal slices 
were stained using TUNEL and photomicrographs identified apoptotic cell death with a fluorescent 
marker.  Apoptosis was inhibited at all doses, suggesting that DHEA is protective against QA and is 
preventing neurodegeneration, possibly by exerting an effect through enzyme modulation.  The 
hippocampus is susceptible to neurodegeneration in AD and other pathological disorders related to 
aging, thus protection of hippocampal neurons by DHEA is relevant and provides an avenue for 
investigation of the clinical use of this neurosteroid in AD and other neurodegenerative diseases. 
 
Chapter 5 
 
Cresyl violet, a dye which stains Nissl substances purple, was used to identify and evaluate any 
morphological changes after the bilateral hippocampal injection of the neurotoxin QA in rats 
receiving daily subcutaneous injections of various doses of DHEA over two weeks.  
Photomicrographs showed that DHEA was able to inhibit cell death by preventing loss of cell 
integrity and maintaining morphological conditions at all doses utilised in the investigation.  The 
results concurred with findings in the previous chapters. 
 
Chapter 6 
 
A potent free radical scavenger in the body is the hormone melatonin, the chief product of the 
pineal gland.  This chapter investigated the influence of DHEA on pineal glands in culture to 
ascertain the effect, if any, on pineal indole metabolism.  It was established that DHEA does not 
result in a significant change in the production of melatonin, but there is a significant decrease in 
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the concentration of serotonin/methoxytryptamine, prompting speculation that overall metabolism is 
increased without altering the relative amounts of each metabolite.  A significant increase of N-
acetylserotonin was observed, while yhe activity of HIOMT was not altered. 
 
Chapter 7 
 
Since the mechanism of action of the neuroprotective effects established in the preceding chapters 
is unknown and the importance of metal ions in neurodegeneration is well-researched, the potential 
interaction of DHEA with two metal ions, Cu(II) and Fe(III), was investigated using UV/VIS 
spectroscopy and electrochemistry.  The spectroscopic study showed that the addition of both 
these metal ions results in a decreased absorbance and a shift to shorter wavelengths, indicative of 
a possible metal ligand interaction.  This was further explored using electrochemistry, the results of 
which demonstrated that DHEA may have a weak interaction with these metals, but also 
highlighted the fact that more extensive study was required.  The reduction in peak and shift to 
more negative potential in voltammograms indicates Fe(III) is becoming more difficult to reduce, 
which is a function of ligand interaction.  However the results suggest that any interaction of this 
steroid with either Cu(II) or Fe(III) is weak. 
 
General Conclusions 
 
Thus, there is merit in the statement that DHEA has neuroprotective properties.  The mechanism of 
this neuroprotection is unclear but the findings of this thesis suggest that it is not due to an 
inhibition of superoxide radical generation, nor is it due to an increased production of the anti-
oxidant melatonin. DHEA was shown to preserve normal neuromorphology and reduce the 
incidence of apoptotic cell death in the presence of QA.  There appears to be a weak nteraction 
between DHEA and the two metal ions under investigation, Fe(III) and Cu(II), and this may play an 
important role physiologically. 
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Further Studies 
 
Although there has been much investigation into dehydroepiandrosterone, particularly over the last 
ten years, there are still many questions which are unanswered.  The preceding chapters have 
highlighted some of these issues, which will be further discussed in the paragraphs below. 
 
Observing the recovery of rats after intrahippocampal injection with quinolinic acid lead to the 
suggestion that a further behavioural study would be of value.  Rats in the groups receiving DHEA 
experienced seizures which were relatively shorter and less severe than those experienced by the 
control group.  A more extensive study, possibly evaluating the dose-dependence of this 
phenomenon would be of value in the future.  After recovery from surgery, rats in the control group 
displayed the classic symptoms of an Alzheimic rat: stiff tail, glazed eyes, and a generally unkempt 
coat suggesting that the rat no longer cleans itself adequately.  Rats also appeared more anti-
social.  Rats receiving all concentrations of DHEA did not display these characteristics to the same 
extent, once again suggesting that DHEA is reducing the amount of neural damage caused by QA.  
Further behavioural studies may be of value. 
 
The literature regarding the effectiveness of DHEA or its sulphated ester in preventing seizures is, 
unfortunately, not conclusive.  Budziszewska et al, (1998) demonstrated that DHEAS, along with 
other neurosteroids, has be shown to significantly increase the dose of NMDA required to produce 
clonic convulsions in 50% of tested animals (CD50), while Hansen et al (2003) have demonstrated 
that the sulphated ester of DHEA is neither anticonvulsant nor antiepileptogenic.  DHEA itself has 
not been well-documented, providing further evidence that further study would be beneficial. 
 
Chapter 6 demonstrated the effect of DHEA in pineal glands in culture but further work should be 
carried out to determine the effect on pineal indole metabolism in vivo, since an in vitro model 
cannot completely replicate the brain environment.  Although the incubation conditions have been 
optimised, the impact of other endogenous substances in the brain and the interaction with 
   
  9: Further Studies 
 
  116 
enzymes has not been assessed.  Also, the organ culture can not mimic physiological levels of 
DHEA, which differ throughout the brain, as mentioned previously.  
 
Many researchers suggest that rodents are unsuitable for obtaining results which may be 
extrapolated to humans since these have minimal endogenous DHEA(S).  These workers caution 
that these results should not be used to promote DHEA supplementation in human.  Rather, these 
discoveries in rodent models can be used as targets for future research.  There is also much 
debate over DHEA concentrations being tested in animals and humans and whether these doses 
should be pharmacological or physiological.  This view may also be addressed in terms of the 
restoration of levels to those experienced in youth, or to raise circulating levels, irrespective of 
serum concentration.  
 
Zhang et al (1999) demonstrated that DHEA and melatonin exert a synergistic effect on T-cell 
proliferation and Vitamin E levels in retrovirus infected and unaffected rats.  The combined action of 
DHEA and melatonin warrants further investigation since both these hormones exhibit an age 
related decline and are affected by circadian rhythms.  Both have been revealed to have a 
favourable effect on immune response, and both display anti-oxidant properties (Oreintreich et al, 
1984; Southgate, 1998). 
 
This thesis investigates the potential interaction between DHEA and two metal ions in Chapter 7, 
which revealed that the steroid may be interacting weakly with both these ions.  A more 
comprehensive metal-ligand examination may prove fruitful in determining how DHEA is exerting 
its neuroprotective effects.  During the electrochemical investigation supplementary scans with 
Cu(II) suggested that the interaction may be time dependent and further investigation is necessary.  
Thus, further knowledge of the potential time-dependent degradation would be beneficial.  
Additionally, light-dependent degradation could also be examined. 
 
The interaction of DHEA with receptors – either an unidentified DHEA(S) specific receptor or a host 
of steroid specific receptors – must be better characterised and is integral to the understanding of 
the unestablished mechanism of action of DHEA. 
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DHEA, as previously mentioned, has been identified as a neurosteroid.  This compound is thus 
synthesised both by the adrenal glands and the brain itself.  Although various scientists have 
investigated the origin and fate of human DHEA and its sulphate derivative more understanding is 
necessary of the movement of DHEA in the body and the relationship between DHEA and DHEAS.  
 
As noted in the literature review, DHEA is a pleiotropic hormone and the extent of the effects of 
DHEA in the human body in still unclear.  More work must be directed at determining whether such 
effects are attributable to DHEA itself, levels of DHEAS as a circulating reservoir or of downstream 
metabolites such as progesterone, oestrogen and testosterone.  The literature review also outlined 
the various effects of DHEA in the body currently identified and the potential therapeutic 
opportunities in manipulating serum levels must be explored, both peripherally as a steroid and 
centrally as a neurosteroid.  Clinically, more research is necessary into the benefits of replacement 
therapy of DHEA in the elderly and in those with any form of pathophysiological deficiency.  The 
therapeutic effects on well-being, mood or sexuality, irrespective of endogenous DHEA(S) levels 
must be further explored (Allolio & Arlt, 2003).  To this end, a better characterisation of the 
pharmacokinetics of both DHEA and DHEAS is also necessary.  
 
The age-related decline in DHEA is well documented (Oreintreich et al, 1984, Orentreich et al, 
1992) and although work has been carried out to investigate the effects of lowered DHEA(S) levels 
in the elderly and the impact of raising these levels to the normal physiological range for those in 
the third decade of life, more attention must be played to the effects DHEA has during development 
and adolescence, when these levels are still increasing (Arlt et al, 1998; Arlt et al, 1999; Ceserini et 
al, 2000).  
 
Wick (2002) is not alone in cautioning against the labeling of “anti-aging” supplements from a 
sociological standpoint.  He argues that while many substances may or may not be efficacious, 
their irresponsible marketing may result in potential physical or economic harm, so responsible 
investigation of DHEA is necessary to dispel any myths surrounding its possible uses. 
Appendix A: Animal Care 
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The animals used were adult male Wistar rats, purchased from the South African Institute for 
Medical Research, Johannesburg, South Africa.  Animals were housed under artificial illumination 
(approximate intensity = 300 μWatts/cm2) with a daily photoperiod of 12 hours with lights 
commencing at 06:00.  The animal house temperature was maintained within the range 20 – 24° 
Celcius and an extractor fan ensured constant removal of stale air.  The rats were housed at five 
per cage with food and water provided ad libitum.  Cages were constructed of an opaque plastic, 
with metal grid floors and covers.  Cages were cleaned regularly.   
The protocol was in accordance with, and was approved by, the Rhodes University Ethics 
Committee. 
All efforts were made to minimise animal suffering and conserve animal resources. 
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The malondialdehyde calibration was obtained by preparing solutions of MDA over a range of 
concentrations and reading the absorbance of the thiobarbituric acid reactive species at 532nm as 
described in Section 2.2.1.3
Appendix C: Diformazan Calibration Curve  
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The diformazan calibration curve was obtained by preparing solutions of NBD over a range of 
concentrations and reading the absorbance at 560nm as described in Section 3.2.1.3 
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The protein assay calibration curve was obtained as described in Section 3.2.1.4, according to a 
modified method of Lowry et al (1951). 
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